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The role that myeloid innate immune cells play in neurodegeneration has long 
fascinated researchers because of the apparent changes of these cells found in all 
neurodegenerative diseases. However, it has become clear that the different parts or 
compartments of a neuron that traverse different anatomical environments degenerate at 
different times. Since there are myeloid cells around all of these neuronal compartments, 
answering the question of how myeloid cells impact the process of compartmentalized 
neurodegeneration is challenging. Further complicating this question is the fact that these 
cells can rapidly change their morphology and function in a process termed activation. In 
these activated states, myeloid cells have the capacity to regulate many aspects of 
neuronal damage and repair. Lastly, these myeloid cells are derived from different 
lineages that may play different roles in neurodegeneration.  
Many authors have manipulated myeloid cells by loss of the receptor (CX3CR1) 
for the chemokine fractalkine and arrived at contrasting and context-dependent results 
even within models of the same neurodegenerative disease. Few studies have examined 
loss of fractalkine signaling in multiple compartments and even fewer have collected 
these data for each animal. Therefore, it remains unknown how loss of fractalkine 
signaling affects compartmentalized neurodegeneration.  
Since the chronic mouse model of glaucoma, the DBA/2J, grants easy access to 
different degenerating retinal ganglion cell (RGC) compartments, it is an ideal system to 
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determine how myeloid cells affect neuronal compartmentalized degeneration. The 
DBA/2J also features changes to myeloid cells, including microglial activation as early as 
3 months and macrophage infiltration at 10 months. We generated DBA/2J mice lacking 
CX3CR1, and determined that this differentially affected RGC compartmentalized 
degeneration by increasing numbers of RGCs with a marker of disrupted axonal transport 
while not affecting RGC transcriptional dysregulation or optic nerve degeneration. Loss 
of CX3CR1 did not increase microglial activation overall but increased macrophage 
infiltration. However, numbers of infiltrating macrophage did not correlate with RGC 
pathology. We found that early microglial activation was composed of resident microglia 
and that high levels correlated strongly with later optic nerve degeneration. All together, 
these data implicate the resident microglia in disease progression in neurodegeneration. 
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Challenges and fundamental aspects of neurodegeneration 
 
For most of our adult life, we take for granted the intricate and many faceted 
control that the central nervous system has over so many life functions, which is why the 
relentless breakdown in neurodegeneration is such a betrayal. The cause of these diseases 
is unknown and with age as a common risk factor, the prevalence is increasing with the 
percentage of older individuals in the population. For example, the number of 
Alzheimer’s disease cases is projected to triple by 2050 from its current number of 5 
million cases (Hebert et al., 2013). Furthermore, patients can spend potentially a decade 
or more experiencing progressively worse symptoms. For all these reasons, 
neurodegenerative disease is a serious health concern now and even more so in the future. 
Diagnosis of these diseases is made when patients can’t remember, can’t move, or can’t 
see, reflecting an irreversible loss of neurons. Therapies are variously efficacious at 
slowing the progress of symptoms speaking directly to a lack of biological knowledge of 
this process.  
Despite many years of study, the biology driving neurodegeneration stubbornly 
remains a mystery. Still unanswered are the fundamental questions of when and where 
does neurodegeneration begin? A main reason for this is the increasing number of 
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observed pre-apoptotic changes that occur in different parts of a neuron before a final 
commitment to apoptosis. However, these observations also suggest that investigating 
these changes in a compartment-specific manner might facilitate a better understanding 
of pathogenic events that occur before neurons commit to cell death.  Neurons are 
structurally unique cells, with >99% of their cell volume in their projections that can 
extend up to 1 meter in length (Morfini et al., 2009; Rishal and Fainzilber, 2014). In 
keeping with this amazing extension, neurons traverse a number of different physical 
environments and interact with many cellular systems making their study during 
neurodegeneration spatially challenging. Since neurodegeneration takes place over a 
protracted course with changes to these different cellular systems, there is an additional 
temporal challenge to studying this process. All together, these facts have transformed the 
study of neurodegeneration from examining the end readouts such as death or apoptosis 
of neurons, to investigating how and in what order a neuron systematically takes itself 
apart over time. A related question concerns defining what the cellular systems are that 
take part in this degeneration. In light of these challenges/obstacles, it is perhaps not 
surprising that mechanistic knowledge of neurodegenerative diseases is still elusive.  
There are three fundamental questions that remain unanswered in 
neurodegeneration and the lack of answers has led to obstacles in detection, treatment, 
and potential prevention of neurodegenerative diseases: 1) when and how does 
neurodegeneration initiate?, 2) what is the subsequent sequence of neuronal 
degeneration?, and 3) what are the contributions of non-neural cells to the process of 
neurodegeneration? This last question is particularly intriguing, because understanding 
the roles of these surrounding support cells could be useful in designing new therapeutic 
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targets or might be harnessed to support ailing neurons, thus delaying or preventing the 
degenerative process.   
Despite the fact that neurodegenerative diseases affect vastly different parts of the 
central nervous system (CNS), such as the spinal cord in amyotrophic lateral sclerosis 
(ALS), or the retina in glaucoma, they do share common features. A cardinal feature is 
the targeting of one particular neuronal type, such as the retinal ganglion cell (RGC) in 
glaucoma, while other types of neurons in the immediate vicinity are at first apparently 
unaffected but may degenerate secondarily later in the disease (see Figure 1.1A, Calkins, 
2012). The pattern of decline and death in the affected neuronal type is both progressive 
(see Figure 1.1B, gets worse over time) and asynchronous (see Figure 1.1B, affects some 
but not all of the targeted neuronal type at a given time). Given its complexity, age is a 
common but poorly understood risk factor for all of these diseases. Whether this 
progressive and asynchronous pattern reflects unknown sensitivities of different subsets 
of these neurons at different locations or perhaps unknown disease insults occurring at 




In addition to the questions surrounding the degeneration of populations of 
neurons, there are many questions about the pattern of degeneration of an individual 
neuron.  Since neurons are so structurally spread out in order to perform their function, 
compartments then sustain insults, signal those insults to other compartments, and can 
degenerate in a compartment-specific but finally overlapping manner. While the ability of 




Figure 1.1: Neurodegenerative diseases have features in common. (A) 
Neurodegeneration affects one type of neuron but not others. On the left is listed the 
neurodegenerative disease and on the right the affected class of neurons (B) 
Neurodegeneration is progressive. Top – the progressive nature of neurodegeneration is 
illustrated as a neuron goes from declining to apoptotic. Damage to different parts of the 
neuron is indicated by red stars. Middle – a time course depicting pre-apoptotic neuronal 
changes preceding symptoms as disease advances from preclinical to an advanced stage. 
The shape of the curve reflects the asynchronous nature of neurodegeneration that does 
not proceed in a linear manner.  
Reproduced from “Perspectives on molecular targeted therapies and clinical trials for 
neurodegenerative diseases”, by Masahisa Katsuno, Fumiaki Tanaka, Gen Sobue, 83, 










resiliency to the system, it makes it challenging to determine a sequence in 
neurodegeneration (Conforti et al., 2007). This process of neuronal compartmental 
degeneration makes it critical to study neurodegeneration in systems that grant access to 
these compartments so that degeneration can be assayed/examined in multiple 
compartments at the same time.  
The different CNS environments through which a given neuronal compartment 
travels are made of cellular systems that include many components: vasculature, 
astrocytes, oligodendrocytes, and cells of the myeloid innate immune system. Elegant 
studies in ALS amongst others (Ilieva et al., 2009), have demonstrated that these 
components can greatly contribute to the progression of neurodegeneration. For example, 
expression of a mutated version of superoxide dismutase in mouse models of familial 
ALS in astrocytes or microglia drives disease progression but does not affect disease 
onset (Ilieva et al., 2009). Of these glial cells, the myeloid innate immune cells have 
fascinated investigators for over 100 years because of their morphologic and functional 
changes in all neurodegenerative diseases (Kettenmann et al., 2010). This then raises a set 
of interesting questions: how is the crosstalk between neurons and myeloid cells affected 
during neurodegeneration and how do changes in these cells affect the common features 
of neurodegenerative diseases (Jurgens and Johnson, 2012)? 
 
Introduction to the myeloid innate immune system: resident  
microglia and macrophages 
 
Amongst these glial cells, the role that cells of the myeloid innate immune system 
may play in neurodegeneration is particularly intriguing since these cells are very plastic 
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and have the capacity not only to contribute to neurodegeneration but also potentially to 
help ameliorate it. The innate immune system is composed of cells such as neutrophils, 
mast cells, and myeloid cells including microglia and macrophages that recognize 
conserved motifs of invading pathogens or molecules that indicate cellular stress. 
Specifically, the myeloid arm of the innate immune system is composed of cells of the 
myeloid lineage that take up residence in many tissues, including circulating monocytes 
in the blood, Langerhans cells in the skin, Kuppfer cells in the liver, and microglia in the 
CNS (Murray and Wynn, 2011). Collectively, these cells are referred to as the 
mononuclear phagocyte system (MPS). Monocytes in these different organs have 
multiple roles, they can be pro- or anti-inflammatory depending on the context, present 
antigen to stimulate adaptive immunity, clear away cell debris, and prevent autoimmune 
responses to this debris (Murray and Wynn, 2011). In particular, the ability to clear away 
debris has been hypothesized to be of benefit in neurodegenerative diseases, including 
Alzheimer’s, where there is a prominent deposition of amyloid-β protein aggregates. 
However, despite the promise of this system to clear protein aggregates or cellular debris, 
there have been recent, spectacular, and expensive failures to ameliorate 
neurodegeneration by manipulating this process (Karran and Hardy, 2014), perhaps 
reflecting a lack of understanding of the MPS.  
One possible reason for these failures has been the lack of specific markers to 
identify the origin of cells of the MPS. The MPS is composed of yolk sac-derived 
phagocytes born very early in embryogenesis as well as hematopoietically-derived 
macrophages that may be present during disease. For example, seminal studies from 
several authors (Ginhoux et al., 2010; Kierdorf et al., 2013; Mizutani et al., 2012) 
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determined that the resident myeloid cells of the CNS, microglia, are derived exclusively 
from yolk sac erythroid-myeloid progenitor cells born around E8 in the mouse. 
Thereafter, microglia establish a stable population in the retina and brain that is 
supplemented by a very low rate of local proliferation (Ransohoff and Perry, 2009) that 
can be increased in the event of microglia depletion by a resident, as yet unidentified, 
microglial stem cell (Elmore et al., 2014). In contrast, hematopoietically-derived 
macrophages originate in the aorta-gonad-mesonephros region before expanding in the 
fetal liver and finally within the bone marrow (Prinz and Priller, 2014). The existence of 
distinct origins for different cell types has led to the hypothesis that such cells play 
different roles in neurodegeneration (Prinz et al., 2011).  
Microglia have been implicated in several neurodegenerative diseases, including 
ALS, Huntington’s, and Parkinson’s disease (Prinz et al., 2011).  In the majority of cases, 
the mechanisms implicated in microglial-driven pathology involve toxic gains of function 
with increased secretion of pro-inflammatory cytokines like IL1β and subsequent 
generation of reactive oxygen species (ROS; Prinz et al., 2011). These cytokines and 
ROS then further damage neurons in a local manner potentially explaining why only 
some of the affected neuronal population die when toxic proteins are expressed in all of 
them. However, in addition to microglia, other studies have implicated peripheral 
macrophages in the disease progression of multiple sclerosis and Alzheimer’s disease 
(Ajami et al., 2011; El Khoury et al., 2007).  
Further complications come from studies in mouse models of ALS, showing that 
one branch of the myeloid innate immune system may affect the other. Butovsky et al. 
(2012) found in mouse models of ALS that resident microglia express the chemokine 
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CCL2 that summons CCR2-expressing macrophages. They also showed that once in the 
spinal cord, these CCR2 macrophages proliferated while the resident microglia 
underwent apoptosis. Observations such as these raise two questions in the 
neurodegenerative field: what arm of the MPS is responsible for what facet of 
neurodegeneration and how do these arms interact with or influence each other? Lack of 
complete understanding of these cells’ roles may have contributed to the failure of 
attempts to manipulate these myeloid cells by anti-amyloid-β antibodies (Tayeb et al., 
2013) either because they targeted the wrong branch of the MPS or because one branch 
was manipulating the activity of the other.   
 
New markers for resident microglia and peripheral macrophages 
 
In order to begin addressing which myeloid branch is responsible for disease, 
several authors have recently identified markers that can distinguish resident microglia 
from infiltrating macrophages in the adult mouse through extensive profiling experiments 
(Butovsky et al., 2014; Butovsky et al., 2012; Hickman et al., 2013; Saederup et al., 
2010; Zhang et al., 2014). All resident microglia and macrophages express the 
cytoskeleton-associated gene Iba1 (see Figure 1.2A & 1.2B) and at some point during 
their development, express the receptor CX3CR1 for the chemokine, fractalkine (Jung et 
al., 2000; Prinz and Priller, 2014; Yona et al., 2013). In the case of some resident myeloid 
cells such as Kuppfer cells, CX3CR1 is expressed during development but subsequently 
turned off in adulthood, while in others such as circulating monocytes, there are subsets 
that express more or less CX3CR1 (Yona et al., 2013). Indeed, a mouse with GFP 
knocked into the CX3CR1 gene locus (CX3CR1 gfp/+ mice) has become a crucial tool in 
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studying microglia under physiologic or pathologic conditions (Jung et al., 2000). The 
CX3CR1 GFP/+ heterozygous and CX3CR1 GFP/GFP homozygous mouse has been used for 
live imaging of myeloid cells such as microglia (Bosco et al., 2015; Tremblay et al., 
2010) as well as for testing the role of FKN in a wide variety of models of CNS injury or 
disease (Wolf et al., 2013). However, in this mouse, GFP labels all myeloid cells, as well 
as NK cells, and some subsets of T cells, making interpretation of results problematic 
(Jung et al., 2000). In contrast, the purinergic receptor, P2Y12, and the transforming-
growth factor B receptor 1 (Tgfbr1) were found specifically to label resident microglia 
(Butovsky et al., 2014), while the expression of a different chemokine receptor, CCR2 is 
restricted to circulating macrophages (Saederup et al., 2010).  
These markers are critical to the study of neurodegeneration because it has long 
been thought that these different lineages may play different roles in the healthy and 
diseased CNS (Prinz et al., 2011). Classically, the resident microglia were thought of as 
sentinels, patiently waiting for infection or injury to the CNS before they change their 
phenotype to address the problem (Kettenmann et al., 2010). This change in phenotype, 
termed microglial “activation”, is best characterized by a change in microglial shape from 
a small cell body with many ramified processes, to a shape with shorter, stouter 
processes, and finally to an amoeboid shape under very activated conditions (see Figure 
1.2C). In this amoeboid state, microglia are thought to phagocytose material and 
potentially secrete pro-inflammatory cytokines as well as reactive nitrogen and oxygen 
species to combat the problem and alert the peripheral immune system of ongoing 
infection or damage (Kettenmann et al., 2010). However, in this amoeboid state, a very 





Figure 1.2: Microglia change shape when they become activated. (A) Retinal whole 
mount stained for Iba1. (B) Higher magnification view of the red box outlined in A. 
Depicted are the three easily distinguished Iba1+ elements. In the white circle is an 
amoeboid shaped cell distinguished by lacking all processes. In the green square is a 
branched cell with a small cell soma and branched processes. In the orange rectangle is a 
perivascular cell with two prominent processes on polar opposite sides of the cell. (C) 
Sequence of microglial activation from a small cell with many branches (1), to a cell with 
an enlarged soma (2), and then a cell with shorter processes as they are retracted (3). A 
fully activated microglia would resemble the amoeboid Iba1+ cell in the white circle 






macrophages infiltrate peripheral tissues under inflammatory conditions but once there, 
they too can display a number of different phenotypes. Furthermore, these macrophage 
phenotypes appear to change with time although it is not currently clear whether this is 
the result of infiltration of different macrophages subtypes over time or a change in the 
phenotype of the already present macrophage (Mosser and Edwards, 2008).  
In addition to this simple scheme of resident microglia as sentinels and 
macrophages as responding effector cells, resident microglia play important roles in CNS 
development. During development, an excessive number of neurons and synapses are 
generated and the resident microglia with their phagocytic ability are key in clearing 
away these cells and connections so that an orderly circuit can be established. In this 
context as well, the dynamic nature of microglia has been recognized since they play not 
only a crucial phagocytic role but also can induce apoptosis of excess neurons, for 
example as with Purkinje neurons in the cerebellum (Ransohoff and Perry, 2009).  
During the postnatal and adult periods, however, homeostatic roles for microglia 
are controversial. It has been demonstrated through sophisticated two-photon imaging 
experiments that the resident microglia constantly remodel and move their processes 
(Davalos et al., 2005; Nimmerjahn et al., 2005), suggesting a homeostatic role. Since 
microglia exist in an orderly, tiled mosaic in the CNS and retina wherein the cell body is 
thought to stay fixed and the arbor of processes from one microglia does not overlap the 
territory of another, the movement of these processes is estimated to screen the entire 
CNS every two hours (Hanisch and Kettenmann, 2007). The purpose of this movement 
under any given circumstance is unknown but Davolos et al. (2005) showed dramatic, 
real-time reaction of microglial processes towards a laser-induced injury within minutes  
  
12 
while Tremblay et al. (2010) demonstrated that this movement can be modified by visual 
activity. 
Other authors have ablated microglia in order to determine if they play 
homeostatic roles but have so far come to conflicting conclusions. Parkhurst et al. (2013) 
depleted microglia by using the CX3CR1 promoter to drive expression of the diphtheria 
toxin receptor. After verifying robust CNS microglia depletion at one week (~85% 
depleted), they found disrupted synaptic plasticity, slower acquisition of motor and 
memory learning behaviors, and a reduction in proteins involved in excitatory 
glutamatergic synaptic transmission in the mice. A second study from Elmore et al. 
(2014) depleted microglia pharmacologically with a CSF1R antagonist and achieved 
nearly complete microglia depletion at 21 days that could be sustained up to 2 months 
with repeated dosing. In contrast to Parkhurst et al. (2013), mice depleted of microglia in 
this way displayed no behavioral deficits in terms of anxiety or hippocampal-dependent 
learning tasks. Though these two authors used different methods to deplete microglia, the 
debate on the physiologic role of resident microglia in the adult CNS continues.  It 
remains unknown therefore whether depletion of microglia in the adult in any given 
disease context at the same time alter microglial homeostatic functions, thus confounding 
the interpretation. To date then, it remains unknown if neurodegeneration features a loss 







Involvement of the myeloid innate immune system in  
neurodegeneration 
 
Myeloid lineage-specific markers may open new avenues into studying the 
homeostatic roles of resident microglia and may enable researchers to more clearly define 
how these cells affect neurodegenerative disease.  In fact, using tools such as the 
CX3CR1 gfp/+ mouse has proven useful to describe changes in the different myeloid cell 
populations but understanding of cell-specific roles has remained elusive, in part due to 
technical challenges.  For example, to answer the longstanding question of whether 
peripheral macrophages seed the CNS, Ajami et al. (2007) used elegant but complicated 
parabiosis and irradiation experiments involving the CX3CR1 gfp/+ mouse and showed 
that peripheral macrophages do not seed the CNS even in a mouse model of multiple 
sclerosis. In contrast to requiring parabiosis and irradiation, El Khoury et al. (2007) used 
a mouse expressing RFP under the control of the peripheral macrophage marker CCR2, 
and were able to demonstrate that peripheral macrophages rather than the resident 
microglia were responsible for phagocytosing vascular amyloid-β plaques. Further, using 
the resident microglial specific marker CD39, Butovsky et al. (2012) were able to 
demonstrate that resident microglia may be recruiting macrophages through CCL2 
expression and then dying by apoptosis once these cells arrive and proliferate in mouse 
models of ALS. 
Myeloid lineage-specific markers may better define a crosstalk between resident 
microglia and macrophages and may help to address the question of whether microglia 
lose neuroprotective function with age that may contribute to neurodegeneration. The 
finding that resident microglia in the retina and brain are a stable population (Ransohoff 
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and Perry, 2009), in combination with age being a common risk factor in 
neurodegenerative diseases, has led some authors to suggest that resident microglia are in 
fact neuroprotective but that they lose function with age (Streit and Xue, 2014). In 
support of this microglia aging hypothesis, Streit and Xue, (2014) noted that with age, 
microglial processes appear dystrophic, and speculated that aged microglia are therefore 
less able to support ailing neurons.  
In contrast to the microglia aging and loss of function hypothesis, other authors 
have noted an age-related increase in microglial activation albeit using general myeloid 
markers. For example, Mouton et al. (2002) described an increase in microglial number 
with age in mice, and Damani et al. (2011) showed that aged microglia appear more 
activated with reduced process arbors and remodel their processes more slowly. All of 
this suggests a toxic gain of function as well as a possible alteration in how microglia 
interact with peripheral macrophages. However, relying on microglia shape change to 
indicate altered function may be too simplistic since microglia need not change shape to 
change phenotype (Kettenmann et al., 2010).  
The mechanism most frequently cited for a microglial toxic gain of function 
involves increased secretion of pro-inflammatory cytokines and reactive oxygen species. 
For example, increased secretion of pro-inflammatory cytokines like Il-1β and Tnf-α by 
activated myeloid cells has been described in animal models of neurodegenerative 
diseases such as Alzheimer’s and Parkinson’s disease (Prinz et al., 2011). Further, pro-
inflammatory cytokines measured in serum have been used to identify Alzheimer’s 
patients amongst blinded samples with 90% accuracy (Ray et al., 2007). However, the 
role of these cytokines in neurodegeneration remains unclear since they can act on 
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neuronal survival or death in a delicate balance (Smith et al., 2012). Lastly, as noted 
above, it is also unclear whether resident microglia or infiltrating macrophages are the 
source of these cytokines. All together then, whether neurodegeneration features a loss, 
gain of function, or both amongst myeloid cells remains unanswered. 
 
Neurons communicate to myeloid cell through ligand-receptor  
systems including the fractalkine signaling system 
 
Regardless of whether myeloid cells become neurotoxic or lose the ability to 
support neurons, it is clear that communication exists between myeloid cells and neurons 
and that this crosstalk is likely altered during neurodegeneration. Both resident microglia 
and infiltrating macrophages respond to neuronal stress and damage through ligand-
receptor systems. These ligand receptor systems act in either a stimulatory or a repressive 
manner with respect to myeloid activation. 
Microglia and macrophages express a wide array of receptors for neuronal stress 
or damage signals, including Toll-like receptors and purinergic receptors such as the 
various P2X receptors (Amor et al., 2010). In contrast, other ligand receptor systems act 
to repress aspects of myeloid activation but with different kinetics. For example, the 
neuronal CD200 to myeloid CD200R system keeps myeloid activation at baseline so that 
with loss of the CD200R, microglia become constitutively activated (Hoek et al., 2000). 
In contrast, the chemokine fractalkine (CX3CL1; FKN) signaling system represses 
microglial activation in response to an insult. Mice with a loss of the fractalkine receptor, 
CX3CR1, have normal appearing microglia at baseline in terms of shape and number 
(Jung et al., 2000). However, upon insult, ranging from injection of the bacterial cell wall 
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component lipopolysaccharide (LPS) or within mouse models of neurodegenerative 
diseases, the microglial activation response is enhanced, with microglia changing into an 
amoeboid shape as well as elevating secretion of pro-inflammatory cytokines (Cardona et 
al., 2006). Importantly for studies in neurodegeneration, FKN signaling has been shown 
to affect age-related changes to microglia. Lyons et al. (2009) showed the FKN mRNA 
and protein are downregulated with age in the mouse brain. Further, Wynne et al. (2010) 
demonstrated a prolonged downregulation of CX3CR1 upon LPS injection that correlated 
with a greater increase in secretion of IL1β in isolated microglia from aged versus adult 
mice. These data suggested that the microglia lacking CX3CR1 over-activated and 
secreted more pro-inflammatory cytokines in response to an insult.  
The apparent lack of microglial activation at baseline and over-activation upon 
insult with loss of CX3CR1 makes this system attractive to study neuronal to microglial 
communication. Fractalkine is also well positioned to orchestrate neuron to myeloid cell 
communication because of its expression pattern in the CNS and unique structure. 
Consistent with a role in neuron to myeloid signaling, FKN is expressed constitutively 
and at high levels in the CNS (with highest levels of mRNA in the cortex, hippocampus, 
and striatum) and on the protein level, mostly on pyramidal, glutamatergic neurons 
(Tarozzo et al., 2003). The 373 amino acid ligand FKN is unique among chemokines 
because the chemokine-signaling domain sits atop a long mucin-like stalk, followed by a 
single pass transmembrane domain, and a short 37 amino acid cytoplasmic tail that has 
not been described to have any signaling motifs (Bazan et al., 1997). Another unique 
feature of FKN is that, because of its structure, FKN can signal in both a membrane-
bound and secreted manner and was found to be a potent chemoattractant for monocytes 
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and lymphocytes but not neutrophils (Bazan et al., 1997).  
The expression pattern and function of the FKN receptor, CX3CR1, is also 
consistent with a role in neuron to myeloid cell signaling. CX3CR1 is the only known 
receptor for FKN and is expressed by myeloid cells, NK cells, and subsets of T cells 
including microglia in the CNS (Jung et al., 2000). CX3CR1 is a 7 pass transmembrane 
Gα-i protein coupled receptor thought to mediate different effects depending upon 
binding by different forms of FKN.  For example, the receptor modulates adhesion in 
concert with integrins (Fujita et al., 2012) when bound by membrane bound FKN and 
chemotaxis when bound by soluble FKN (Imai et al., 1997).  
  
Phenotype of CX3CR1 deficient mice at baseline and in  
neurodegenerative models 
 
 Jung et al. (2000) generated a mouse that is frequently used to study FKN 
signaling by ablation of the CX3CR1 gene and protein through knock-in of the gene for 
EGFP. This strategy simultaneously removes CX3CR1 expression and labels the cells 
that were expressing or had expressed CX3CR1. CX3CR1 gfp/gfp mice are viable and 
fertile with normal lifespans (Jung et al., 2000). However, despite this seeming lack of 
effect of loss of fractalkine signaling at baseline, recently, Zhan et al. (2014) determined 
that mice deficient for CX3CR1 show delays in microglial population of the CNS. This 
delay correlated with a failure to appropriately prune synapses developmentally and 
autistic behaviors later in adulthood.  
Most studies have examined FKN signaling in a wide range of neuronal injury 
and degeneration models and demonstrated context-dependent and contrasting results. 
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For example, ablation of CX3CR1 signaling increased neuronal loss in mouse models of 
Parkinson’s disease and ALS (Cardona et al., 2006) but reduced infarct volume in models 
of stroke (Denes et al., 2008). In both of these examples, CX3CR1 null microglia 
appeared more activated in terms of shape and number. To date, not many studies have 
examined the physiologic role of FKN within nondiseased mice, but Liang et al. (2009) 
determined that microglia lacking CX3CR1 remodel their processes more slowly in the 
retina which could indicate that resident microglia may be somehow functionally 
compromised.  
One caveat to all these experiments is that FKN signaling occurs throughout the 
entire animal and thus global loss of function may alter organ systems that communicate 
with the CNS. For example, Kim et al. (2011) showed that intestinal macrophages 
lacking CX3CR1 failed to form transendothelial dendrites used to sample the intestinal 
lumen while Landsman et al. (2009) showed that CX3CR1 gfp/gfp mice were deficient in 
the Ly6Clo CX3CR1hi subset of circulating macrophages. Lastly, Lee et al. (2013) found 
that FKN signaling can regulate insulin secretion. Since these systems may impact CNS, 
development or function global loss of FKN signaling may well confound interpretation 
of how loss of FKN signaling affects neurodegeneration. To date, studies involving the 
loss of FKN signaling (either in a membrane-bound or soluble manner) have relied on 
whole animal ablation of FKN signaling.  
 
Myeloid functions regulated by fractalkine signaling 
 
As is evident from the studies of Liang et al. (2009), Kim et al. (2011) , and 
Cardona et al. (2006), the list of myeloid functions regulated by FKN signaling has 
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grown beyond the originally described functions in adhesion and chemotaxis (Bazan et 
al., 1997). This could explain in part the contrasting results seen in different disease and 
injury models with manipulations to the FKN system since these additional functions of 
phagocytosis, secretion of pro-inflammatory cytokines, infiltration of macrophages, and 
others may differentially affect disease progression depending on the model. In 
particular, the ability of FKN signaling to affect infiltration of macrophages may have 
confounded earlier studies (Cardona et al., 2006) that described an increase in microglial 
activation, especially since it is now appreciated that macrophages can alter 
neurodegenerative progression (Ajami et al., 2011; El Khoury et al., 2007). Further, it has 
been determined that fractalkine signaling interferes with the signaling of another 
chemokine system: the CCL2/MCP1 to CCR2 chemokine system that is crucial in 
trafficking of infiltrating macrophages to sites of inflammation. In contrast to CX3CR1 
that marks all myeloid cells, CCR2 labels peripherally-derived macrophages in the adult 
mouse (Mizutani et al., 2012; Saederup et al., 2010). Vitale et al. (2004) showed that 
soluble FKN reduces chemotaxis of a monocyte cell line to CCL2 and reduced the CCL2- 
stimulated increase in phospho-p38 that in turn stimulates the production of pro-
inflammatory cytokines. Jacquelin et al. (2013) found that in the absence of CX3CR1, 
there was a more rapid increase of CCR2+ Ly6Chi macrophages in the bloodstream and 
spleen post-myeloablation. Consistent with this, these authors also demonstrated that 
CX3CR1 reduced monocyte motility and subsequent release under normal conditions 
within the bone marrow. These studies are consistent with Sennlaub et al. (2013) who 
found that there was an increase of CCR2+ infiltrating macrophages in a mouse model of 
age-related macular degeneration and that ablation of these cells rescued neuronal 
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apoptosis. These studies suggest that with regard to infiltrating macrophages, one role of 
FKN signaling may be to limit the infiltration of a neurotoxic macrophage into the 
diseased CNS.  
FKN signaling regulates not only macrophage infiltration but also phagocytosis 
by these cells which may be important in neurodegenerative diseases that feature cellular 
debris as neurons decline and die. However, conflicting results have been determined 
regarding FKN’s ability to regulate phagocytosis. In particular, Fuller and Van Eldik 
(2008) found that fractalkine stimulates the clearance of apoptotic cells by stimulating 
myeloid cells to secrete the protein Mfg-E8 that tethers apoptotic cells to phagocytic 
cells. In apparent contrast to a pro-phagocytic role for FKN, Lee et al. (2010) found that 
CX3CR1-deficient microglia phagocytose more microspheres and amyloid-β material, 
leading to a reduction in the amyloid-β burden in Alzheimer’s disease model mice. A 
possible explanation for these contrasting results is a differential effect of FKN signaling 
on the phagocytosis of different materials, in this case cell debris or apoptotic cells versus 
protein deposits. In agreement with the idea that FKN may enhance the removal of dead 
or dying cells, CX3CR1 deficiency in a mouse model of Alzheimer’s disease enhanced 
Tau pathology amongst neurons (Bhaskar et al., 2010) while over-expression of FKN 
reduced tau pathology (Nash et al., 2013). Loss of CX3CR1 also prevented the loss of 
neurons at an earlier timepoint (Fuhrmann et al., 2010) in other Alzheimer’s disease 
mice. These disparate results in Alzheimer’s disease mouse models call for a more 
comprehensive examination of different neuronal compartments when the FKN signaling 
system has been perturbed. Ultimately, ablation of CX3CR1 in a myeloid-specific 





Glaucoma as a model of neurodegeneration 
 
The issue of differential effects of fractalkine signaling on myeloid cell lineages is 
compounded in the neurodegenerative field when the concept of compartmentalized 
neurodegeneration is added into the mix (see Figure 1.3A and B). In addition to specific 
myeloid lineage markers, what is needed to unravel this mystery is a model of 
neurodegenerative disease that features easy access to multiple degenerating neuronal 
compartments from the same animal so that they can be compared to one another. In 
many cases, such as Alzheimer’s disease, Parkinson’s disease, and ALS, there are 
technical challenges in studying degenerating neurons that are located within bony 
structures and project axons to even deeper regions of the CNS. Furthermore, it may be 
difficult to get the entire picture when disease is spread over larger cortical areas, as is the 
case with Alzheimer’s disease. In contrast, the neurodegenerative disease glaucoma 
affects neurons within the retina, an outgrowth of the CNS. The eye grants tremendous 
access to degenerating CNS neurons, as evidenced by live imaging studies (Bosco et al., 
2015). In contrast to the cortex, the eye provides a contained, smaller anatomic area 
where all the degenerating neurons are contained as well as a single nerve containing all 
the projections. 
Importantly, glaucoma is a classic neurodegenerative disease in that it is age- 
related, progressive, and targets one type of neuron in an asynchronous manner in the 
same way as Alzheimer’s, Parkinson’s, or ALS. Although glaucoma refers to a number of 




Figure 1.3: Retinal ganglion cell degeneration is compartmentalized in glaucoma. 
(A) A cartoon of a retinal ganglion cell is depicted with the green arrow indicating the 
cell soma, the red arrow transport within the axon, and the orange arrow the distal 
myelinated axon within the optic nerve. (B) Timeline of glaucoma progression from an 
early stage with vision loss to blindness in a late stage. The boxes around the readouts of 
compartmentalized degeneration correspond to the compartment depicted in A. Within 
the boxes are indicated the pathology readout used to measure neurodegeneration in that 
compartment. Within the retina RGCs accumulate axonal cytoskeleton proteins, 
phosphorylated neurofilaments, as a marker of disrupted RGC axonal transport (red box). 
Gene transcription in RGCs is dysregulated with glaucoma progression including 
downregulation of the RGC-specific transcription factor family Brn3 (a, b, and c; green 
box). With glaucoma progression, RGC axons in the optic nerve are lost with a 
subsequent increase in glia and extracellular matrix within the nerve (orange box).   
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retinal ganglion cells (RGCs), while other retinal neurons degenerate secondarily. Since 
RGCs are the ultimate gatherer of visual information in the retina prior to transmission to 
the brain, damage to these cells leads to blindness. Therefore, the glaucomas are 
characterized by particular structural changes that reflect damage to RGCs, including loss 
of neural tissue at the optic nerve head (ONH), a region where all axons of RGCs 
coalesce to become the optic nerve behind the globe. The loss of this neural tissue is 
referred to as excavation of the ONH that deepens as a result of loss of RGC axons. As 
with other neurodegenerative diseases, loss of RGCs is asynchronous, seen as patients 
develop vision loss in particular arcing regions called arcuate scotomas that typically 
extend from the nasal pole to either the superior or inferior pole in an hourglass pattern. 
Reflecting the progressive nature of glaucoma, these arcuate scotomas coalesce, first 
leaving only central vision, and then proceeding to complete blindness (Quigley, 2011). 
Clinically, the ultimate diagnosis of glaucoma depends on two features of structural 
changes in the retina, ONH excavation and visual field loss.  Unfortunately, because 
these changes are progressive, glaucoma is usually diagnosed when irreplaceable neuron 
loss has already occurred.  Treatments at this stage cannot prevent the loss but can only 
slow the process and often not in all patients. 
In an attempt to diagnose and treat glaucoma at earlier stages, a number of risk 
factors have been identified in order to screen patients for the disease. Important risk 
factors include age (as in all neurodegenerative diseases), elevated intraocular pressure, 
and family history (Cook and Foster, 2012). The mean age of glaucoma patients is 60 
years old with a slight preponderance of women over men (55%) and some difference 
among ethnicities with Asians having the highest numbers of affected individuals for all 
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types of glaucoma (Cook and Foster, 2012). Elevated intraocular pressure (IOP; 
considered elevated at >21mmHg) has received much attention since it does increase 
therisk of getting glaucoma, is relatively easy and noninvasive to measure and treat, and 
since lowering IOP seems to delay vision loss in some but not all patients. For these 
reasons, IOP has become the main screening tool and therapeutic target in glaucoma. The 
idea behind elevated intraocular pressure as a pathogenic insult rests on the idea that the 
axons of RGCs traverse very different environments when they coalesce at the ONH with 
its intraocular pressure range of 10-20 mmHg, proceed through the glial lamina, and then 
exit the eye where the intracranial pressure is probably lower at 7-15 mmHg. This then 
creates a point of stress for RGC axons where they exit the back of the eye and it has 
been proposed that as intraocular pressure increases RGC axons become compressed. 
Additionally, RGC axons are not myelinated until a few mm behind the eye, leaving them 
unprotected from injury in this region.  
However, there are many situations where IOP has been shown to be uncoupled 
from RGC degeneration. For example, there are patients who develop glaucoma despite 
having an IOP below 21 mmHg (normal tension glaucoma). Furthermore, patients with 
IOPs above 21 mmHg do not always progress to exhibit glaucomatous changes such as 
ONH excavation and visual field loss (Quigley, 2011). Lastly, in clinical trials, 50% of 
patients with IOPs above 21 mmHg given IOP lowering medications and verified to have 
had a reduction in IOP still progressed to glaucoma (Kass et al., 2002). There are genetic 
associations amongst glaucoma patients with genes that have a role in the front of the eye 
such as the myocilin and optineurin gene that might be consistent with a role in elevating 
IOP but these genes are also expressed in many ocular and nonocular tissues, making 
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interpretations difficult (Wiggs, 2007). It may be better, then, to consider glaucoma as a 
disease of susceptibility of RGCs to insults such as IOP and genetic mutations (Calkins, 
2012), rather than solely focus on IOP as a causative agent.  
 
Acute and chronic animal models of glaucoma 
 
Nonetheless, in keeping with the focus on IOP in human glaucoma, animal 
models of glaucoma also have focused on elevating IOP within the mouse or rat eye. 
There are both acute and chronic/genetic models. The advantages of an acute model are 
that the onset, magnitude, and to some extent the duration of the insult to RGCs can be 
controlled. Elevated IOP has been accomplished by disruption of the veins draining the 
anterior chamber by cautery, photocoagulation, or injection of hypertonic saline. The 
acute model of glaucoma most often used currently involves injection of small 
polystyrene beads into the anterior chamber that physically block the outflow tracks 
(McKinnon et al., 2009) raising the IOP. While these acute models have been useful, they 
have the limitation of introducing an injury, and it remains unknown if this synchronous 
elevation of IOP models what occurs in glaucoma patients over a long time course. In 
contrast, the chronic/genetic models better capture the age-related aspects of 
neurodegeneration and have allowed researchers to study age-related changes to multiple 







Pathogenesis in the chronic mouse model of glaucoma, the  
DBA/2J mouse 
 
The most frequently used chronic, genetic mouse model of glaucoma is the 
DBA/2J mouse. This mouse develops a pigment dispersion glaucoma over a protracted 
time course as the result of spontaneously occurring loss of function mutations in two 
genes: tyrosinase related protein 1b (Tyrp1b) and glycoprotein in nonmetastasing 
melanoma b (Gpnmb). These two genes function in melanosome generation and 
maintenance pathways within the iris so their loss results in iris stromal atrophy and 
dispersion of melanosome debris into the anterior chamber. This debris then clogs 
outflow channels, resulting in increasing IOP over time (Anderson et al., 2002). The 
presence of both mutations as well as the DBA/2J background is necessary to induce 
glaucoma. Bl6 mice with both mutations develop an iris disease but are much less prone 
to glaucoma (Anderson et al., 2006).  Importantly, there is a strain-matched control that 
features restoration of the wild type version of Gpnmb in the presence of the Tyrp1b 
mutation on the DBA/2J background that rescues the animals from glaucomatous 
neurodegeneration (Howell et al., 2007). Interestingly, as in human glaucoma, a greater 
percentage of female DBA/2J mice develop the disease than male mice (Libby et al., 
2005).  Importantly, this model mimics human glaucomas in many ways, including the 
fact that there are likely other genes that are modifying disease expression as well as 
potentially environmental influences on disease onset and severity. 
Again similar to human glaucoma and despite this being a genetically identical 
inbred mouse strain, elevation in IOP, as well as every pathology readout examined in 
DBA/2J mice, occurs asynchronously within the population. This suggests a combination 
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of genetics and unknown environmental factors that results in glaucoma. Analysis of 
pathology in the DBA/2J therefore results in a percentage of mice displaying a given 
pathology at any selected timepoint with a greater percentage of animals being affected 
with time. For example, elevated IOP is first detected in some mice at 6 months with a 
majority (but not all) of animals having elevated IOP at 9 months (Libby et al., 2005). 
For this reason Libby et al. (2005) recommend 40 eyes for analysis of any pathology. 
While this is a fair number of samples and not always followed in the literature, it was 
determined that glaucoma progresses differently between the left and right eye of an 
individual animal in terms of the loss of axons in the optic nerve such that each animal is 
considered an n of 2 (Libby et al., 2005). In spite of some limitations, the DBA/2J is the 
best model of human glaucoma because pathology is age-related, progressive, and 
asynchronous.  
As in human patients, RGCs are the primary neurons affected in the retina of 
DBA/2J mice (Calkins, 2012). RGCs traverse a number of cellular environments with 
dendrites, a cell soma, and unmyelinated axon within the retina that then becomes 
myelinated in the proximal optic nerve. Since each of these cellular compartments 
degenerate at different times, RGCs are an excellent model system in which to study 
compartmentalized degeneration.  Importantly, there are structural and functional 
pathologic readouts directed at the RGC cell soma, axons, and CNS targets that have 
been characterized in the DBA/2J mouse, allowing us to assay the roles of myeloid innate 
immune cells on neurodegeneration in these different compartments (Dengler-Crish et al., 
2014; Libby et al., 2005; Soto et al., 2008). Within the retina, these include measures of 
disrupted RGC gene transcription as well as immunostaining for structural axonal 
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proteins (Soto et al., 2008). Optic nerve degeneration has been characterized both 
structurally (Bosco et al., 2015; Crish et al., 2010; Libby et al., 2005) and functionally by 
assessing antero and retrograde axonal transport (Dengler-Crish et al., 2014). Therefore, 
within the DBA/2J mouse, analysis of the retina and optic nerve can be combined, 
providing a more complete picture of RGC compartmentalized degeneration.  
 
Changes to myeloid cells in the DBA/2J mouse 
 
The DBA/2J mouse is also an excellent model to explore the impact of changes in 
the myeloid innate immune system on neurodegeneration since alterations to both 
resident microglia and infiltrating macrophages occur alongside RGC decline and death. 
Microglia become activated by morphology, proliferate, and upregulate markers of 
activation, such as Iba1, in the DBA/2J as early as 3 months in some animals (Bosco et 
al., 2012; Bosco et al., 2011). Further, it was determined that peripheral macrophages 
infiltrate into the DBA/2J retina at 10 months (Howell et al., 2012), although the 
implication of this for disease progression is unknown. Interestingly, head-only 
irradiation targeting these proliferating microglia at 3 months rescued glaucoma 
pathology and prevented infiltration of macrophages (Bosco et al., 2012; Howell et al., 
2012). These results suggested that this early microglial activation might play a role in 
later RGC pathology. Further implicating microglia in DBA/2J pathology, treating mice 
with the immunosuppressive drug minocycline reduced the loss of axonal transport 
(Bosco et al., 2008). Since good techniques for profiling myeloid cells now exist, 
unraveling the roles of these cells may lead to a targeted, more mechanistic understanding 
of how the innate immune system affects compartmentalized neuronal degeneration.  
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In sum, the DBA/2J mouse offers an excellent model of neuronal (RGC) 
degeneration because it grants relatively easy access to different degenerating 
compartments, the retina and optic nerve. Furthermore, an impact of myeloid cells in 
RGC degeneration within DBA/2J mice has been hinted at but not manipulated in a 
targeted manner. With the tools in hand to examine RGC compartmentalized 
degeneration, I manipulated the myeloid innate immune cell compartment by loss of 




This dissertation details my work in describing how loss of FKN signaling affects 
compartmentalized RGC neurodegeneration, myeloid cell activation, and the identity of 
the myeloid cells that change early and later in glaucoma progression.   
In Chapter 2 of this dissertation, I detail the phenotypic characterization of loss of 
CX3CR1 on RGC compartmentalized degeneration and changes to myeloid innate 
immune cells versus control DBA/2J mice. I found that loss of CX3CR1 affects some 
RGC compartments but not others. Loss of CX3CR1 on the DBA/2J background 
increased the number of RGCs with a marker of axonal transport defects, but changes in 
RGC gene transcription or optic nerve degeneration were unaffected. Furthermore, by 
analyzing multiple RGC compartments in each sample, I was able to propose a logical 
sequence of RGC degeneration, reflecting the readouts measured here, consistent with the 
hypothesis that loss of FKN signaling generates more sick RGCs rather than delaying 
their clearance.  
Loss of FKN signaling has been shown to result in over-activation of microglia, 
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but interestingly, I found that while the myeloid Iba1+ cells were morphologically more 
activated, with more amoeboid shapes, they were not more activated as measured 
molecularly by determination of Iba1 mRNA levels in CX3CR1 null DBA/2J retinas. 
Instead I showed that the amoeboid-shaped Iba1+ cells were infiltrating macrophages 
based on their location in the neurofibrillary layer and the presence of the peripheral 
macrophage marker CCR2. In contrast, the numbers and morphological appearance of 
branched Iba1+ myeloid cells (presumed resident microglia) were unchanged. Thus, loss 
of FKN signaling increased macrophage infiltration but not myeloid activation. 
Interestingly, the numbers of these infiltrating macrophages did not correlate with RGC 
pathology readouts, suggesting that they do not contribute to these processes but might be 
playing some other role in RGC degeneration. What specifically this role(s) is and 
whether this role is detrimental or beneficial has yet to be directly demonstrated.  
Chapter 3 details the use of early microglial activation as a predictive tool in the 
DBA/2J mouse. Given the variable onset of disease in the DBA/2J mouse described 
above, the use of in vivo monitoring of microglial activation used in this study was highly 
innovative. A very high correlation between early microgliosis in the DBA/2J and later 
optic nerve degeneration was determined by novel in vivo imaging and tissue analysis 
techniques. Further, by immunostaining using new markers of myeloid cell origin, the 
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There is a paucity of chronic and genetic models in which myeloid cells including 
microglia and macrophages are manipulated and effects on compartmentalized 
neurodegeneration examined. We determined how ablating fractalkine signaling affected 
retinal ganglion cell (RGC) compartmentalized degeneration and myeloid cell activation 
in a chronic model of glaucoma, the DBA/2J mouse.   
We generated CX3CR1 gfp/gfp DBA/2J mice and analyzed RGC degeneration and 
neuroimmune responses in retina and optic nerve at 10-11 months of age, versus parental 
DBA/2J mice. To assess RGC degeneration, we quantified density of Brn3+ nuclei, 
density of RGCs with somal accumulation of phosphorylated neurofilament (pNF), and 
quantified the extent of axonal loss in the proximal optic nerve. To assess microglial 
activation, we quantified the density of retinal Iba1+ cells by morphology and measured 
Iba1 mRNA.  We determined that amoeboid Iba1+ cells were macrophages by CCR2 
immunostaining. 
CX3CR1 gfp/gfp DBA/2J mice had increased numbers of RGCs with somal pNF, 
although Brn3+ nuclei density and degeneration of the optic nerve were unaffected. Only 
amoeboid but not ramified Iba1+ cells were increased in number, although Iba1 mRNA 
levels were similar between genotypes. Amoeboid Iba1+ cells were identified as 
peripheral macrophages by localization and CCR2 expression, yet numbers of these cells 
did not correlate with measured RGC pathology.   
Loss of fractalkine signaling selectively increased somal pNF accumulation 
without altering other aspects of RGC neurodegeneration in the retina or optic nerve, 
suggesting specific effects on axon transport. Notably, CX3CR1 gfp/gfp DBA/2J retinas did 
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not show altered activation of resident microglial cells, but had significant increased 




The myeloid innate immune system has long been of interest in the field of 
neurodegeneration because of its reactivity to neuronal stress and damage, but also its 
tantalizing ability to support neurons (Czeh et al., 2011; Ilieva et al., 2009). However, 
since it has become apparent that different compartments of a neuron (i.e., the cell soma, 
axons, or dendrites) degenerate along different timelines (Conforti et al., 2007), it has 
been difficult to determine the role of myeloid cells in each of these compartments. 
Further complicating this issue is the possibly different roles of yolk sac originating 
resident microglia or hematopoietically-derived macrophages in neurodegeneration 
(Prinz et al., 2011). Recently, it has become possible to distinguish between resident 
microglia and infiltrating macrophages (Butovsky et al., 2014; Butovsky et al., 2012; 
Hickman et al., 2013; Saederup et al., 2010; Zhang et al., 2014) allowing the roles in 
neurodegeneration of these different myeloid lineage cells to be addressed.  
In order to address the role of myeloid cells in neurodegeneration, many studies 
have manipulated the fractalkine (FKN) signaling system that serves as a major neuron to 
myeloid cell communication system. However, this has led to conflicting results, not just 
between diseases (Wolf et al.), but between animal models of the same neurodegenerative 
disease. For example, loss of FKN signaling is able to reduce amyloid-β burden in one 
model of Alzheimer’s disease (Lee et al., 2010), while increasing Tau pathology in 
another (Bhaskar et al., 2010). At least part of the source of these conflicting results may 
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be the diverse myeloid functions that are regulated by FKN signaling, as well as an 
inability to identify myeloid lineage. For example, FKN signaling regulates cytokine 
secretion, microglia activation, dynamics and migration, survival of subsets of circulating 
monocytes, phagocytosis, and more recently has also been shown to impact infiltration of 
CCR2+ macrophages (Cardona et al., 2006; Landsman et al., 2009; Lee et al., 2010; 
Liang et al., 2009; Sennlaub et al., 2013).  
However, there is a paucity of studies that examine how loss of FKN signaling 
affects multiple degenerating neuronal compartments within the same model of 
neurodegeneration. The DBA/2J mouse model of glaucoma is an excellent experimental 
tool to determine how loss of FKN signaling affects retinal ganglion cell (RGC) 
compartmentalized neurodegeneration, since many quantitative readouts within the retina 
and optic nerve have been well characterized (Bosco et al., 2015; Dengler-Crish et al., 
2014; Libby et al., 2005a; Schlamp et al., 2006; Soto et al., 2008). These include 
downregulation of RGC genes such as the transcription factor Brn3b, accumulation of 
axonal proteins such as phosphorylated neurofilament (pNF) within RGC somata in the 
retina, and loss of myelinated axons with subsequent increase in glia in the optic nerve. 
Furthermore, alterations to both resident microglia and infiltrating macrophages have 
been noted in this model, although the impact of these on RGC compartmentalized 
degeneration remains poorly understood (Bosco et al., 2015; Bosco et al., 2011; Howell 
et al., 2012).  
We therefore ablated FKN signaling on the DBA/2J background by loss of the 
sole FKN receptor, CX3CR1, and determined how this affected RGC compartmentalized 
neurodegeneration, as well as numbers and activation of microglia versus peripheral 
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macrophages within the retina. We find that loss of CX3CR1 affected some neuronal 
compartments but not others by increasing somal pNF accumulation, suggesting reduced 
axonal transport, but not affecting loss of RGC gene transcription or optic nerve 
degeneration. In addition, while microglia numbers and activation appeared unaffected, 
we observed that loss of CX3CR1 increased the infiltration of CCR2+ macrophages into 
the DBA/2J retina, although the numbers of these cells correlated poorly with RGC 
disease readouts.  
 




Homozygous CX3CR1 gfp/gfp DBA/2J mice were generated by breeding an 
existing colony of CX3CR1 gfp/+ DBA/2J mice to homozygosity (Bosco et al., 2015). 
Control DBA/2J mice were originally obtained from Jackson Labs, bred in-house, and 
were refreshed with new breeders every 3 to 4 generations. Experiments and mouse care 
were performed in compliance with the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research, and with the guidelines of the University of Utah 




Perfusion and dissection of retinal tissue and optic nerves for both 
immunohistochemistry and RNA collection were performed as in Bosco et al. (2011). 
Retinal whole mounts were stored in chilled 0.1M PBS overnight at 4oC and utilized the 
next day for immunohistochemistry. Retinal eyecups were cast in gelatin, stored at -80oC, 
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cut at 16um thickness, and placed on Superfrost Plus Slides (Fisher Scientific, Pittsburgh, 




Triple immunofluoresent staining was performed as in Bosco et al. (2011). 
Primary antibodies used in this study included: goat anti-Brn3 (Santa Cruz sc-6026 at 
1:50), mouse anti-phosphorylated neurofilament (NFM and NFH; Dako M0762 at 1:100), 
rabbit anti-Iba1 (Wako at 1:1000), rat anti-CCR2 APC conjugated (R&D Systems 
FAB5538A at 1:10), and rabbit anti-cleaved caspase 3 (BD Biosciences BDB559565 at 
1:500). All Alexa Fluor-conjugated (488, 568, or 647) donkey secondary antibodies were 
used at 1:400 (Invitrogen); Alexa-Fluor 594-conjugated donkey anti-Rat secondary was 
used at 1:200 (Jackson ImmunoResearch Lab). Whole mounts were incubated with 
primary antibodies for 3 days at 4oC and incubated with appropriate AlexaFluor 




All samples were imaged on an inverted confocal microscope (Nikon A1 with 
NIS-Elements software 4.2) using a 20x objective and resonance scanning. Entire retinas 
were imaged using a multipoint acquisition macro of the software, collecting 25 x 25 
fields at 60x magnification (0.41 nm/pixel), each spanning 30-40 µm of the retinal inner 
surface through a step size of 0.8 µm. Maximum intensity projections of stitched, high-
resolution images were then generated for each retina, and all images were identically 
and minimally adjusted for brightness and contrast for analysis. Optic nerves were 
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imaged on a compound BX51 Olympus light microscope using a 60X objective and 
analyzed using cellSens software as 36 high-resolution multipoint images.  
 
Quantification of Brn3+ nuclei 
 
Brn3+ nuclei were sampled within the central 1.77 µm2 of the retina by dividing a 
circle centered on the optic disc into 8 parts (2 dorsal, 2 ventral, 2 nasal, and 2 temporal). 
A 250-µm2 box was placed in each of these areas and the proper plane was verified by 
the presence of blood vessels. When any of these 8 parts of retina visibly differed in Brn3 
density, i.e., had a sector of RGC degeneration within it, a second box was placed. The 
total number of Brn3+ nuclei were tallied and normalized to the area sampled (# of 
boxes).  To be counted, nuclei had to be spherical/elliptical in shape, greater than 1.5x the 
intensity of the background, and not be hyperintense as debris.  
 
Quantification of somal pNF+ RGCs 
 
Cell somas with accumulated phosphorylated neurofilament were quantified in 
the central 1.77 µm2 of the retina. These cells were quantified based on shape (reflecting 
either somatic or somato-dendritic accumulation), intensity being greater than 1.5x the 
background, and size (being greater than 10 µm in diameter).  By toggling on the Brn3 










Quantification of Iba1+ cells 
 
Three categories of Iba1+ cell were determined based on morphology: branched 
Iba1+ cells with a small cell soma and many branches, perivascular Iba1+ cells having 2 
main branches at polar opposite sides of the cell, and amoeboid Iba1+ cells having no 
branches. Branched Iba1+ and perivascular Iba1+ cells were quantified in the central 1.77 
um2 of the retina, excluding the optic disc. Amoeboid Iba1+ cells, being fewer in number, 
were quantified in the entire retina, excluding the optic disc and blood vessels. 
 
Quantification of % axon-free nerve area 
 
The % area within an optic nerve cross-section comprised of glia and extracellular 
matrix but devoid of axons or dystrophic axons was generated by automatic thresholding 
to create binary masks on 8 bit, RGB images as in Bosco et al. (2015). Images were 
minimally adjusted for contrast (0-10 on a scale to 0-100) and sharpness (Gauss Laplace 
between 1.0-1.1 on a scale of 0-2). A mask encompassing the area of the optic nerve 
minus meninges and blood vessels was generated. Non-axonal elements were then 
masked based on their different grey values. The % non-axonal area was then calculated 
by determining the percent of the total optic nerve mask (minus meninges and blood 
vessels) covering by non-axonal elements.      
 
Optic nerve PPD staining 
 
Optic nerve cross-sections were embedded and PPD stained for 28 min using a 
modified protocol as in Bosco et al. (2015) (Calkins et al., 2005; Libby et al., 2005a). 
1um sections were cut on an ultramicrotome with a glass knife, transferred to slides, and 
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Sample preparation, cDNA synthesis, and qRT-PCR were performed as in Bosco 
et al. (2011). Whole retinas were aspirated through a 22-gauge needle and RNA was 
isolated using a Qiagen RNeasy micro kit according to manufacturer’s instructions. The 
mRNA quality was determined on an Agilent Bioanalyzer and samples with RINs less 
than 8 were discarded. First strand cDNA was synthesized using an Invitrogen 
Superscript III First Strand cDNA synthesis kit according to manufacturer’s 
recommendations and quantities determined on a Nano-drop spectrophotometer. qRT-
PCR was performed on an Applied Biosystems 7900HT instrument with QuantStudio 
12K Flex software using an Invitrogen Platinum Sybr Green qPCR supermix-UDG kit 
according to manufacturer’s instructions. A standard curve was generated based on serial 
one-half dilutions from the pooled expression of cDNAs from a large number of 1 to 12 
month DBA/2J animals between 1.0 and 0.03125 all relative to the 1.0 standard. Genes 




GAPDHF: TGCACCACCAACTGCTTAGC; GAPDHR: 
GGCATGGACTGTGGTCATGAG; IBA1F: CCTGATTGGAGGTGGATGTCA; 
IBA1R: GGCTCACGACTGTTTCTTTTTTCC; KIF1BF: 
TTATTGATACATCCATGGGGTC; KIF1BR: TCTCCTGAATACTGGTCACA 







Normality of the data was examined both by histogram distribution and by 
percentage of data falling 1 and 2 standard deviations away from the mean. Individual 
data points are showed, and the means indicated with a solid horizontal bar, with dashed 
horizontal bars denoting +1 and -1 standard deviations. We therefore used a Wilcoxon 
ranked sum test to determine significance with * being a p<.05. Normalized qRT-PCR 




Loss of the CX3CR1 in the DBA/2J mouse does not alter Brn3  
downregulation 
 
Since disruption of Cx3CR1 has been reported to influence neuronal decline in 
other models of neurodegeneration, we sought to determine whether the course of RGC 
decline would be impacted by loss of fractalkine signaling in a model of glaucoma. We 
generated DBA/2J mice homozygous for a CX3CR1-GFP knock-in allele  (Bosco et al., 
2015; Jung et al., 2000), and aged these animals, as well as standard DBA/2J mice, to 10-
11 months of age, when a majority of DBA/2J eyes typically show clear glaucoma 
pathology (Libby et al., 2005a). Since RGC degeneration in the DBA/2J involves 
downregulation of RGC genes, including the transcription factor family, Brn3 (Domenici 
et al., 2014; Soto et al., 2008), we assessed whether loss of fractalkine signaling altered 
expression of Brn3 in CX3CR1-GFP DBA/2J retinas (n =36 ) relative to DBA/2J retinas 
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(n =31 ) (Fig. 2.1 A). We quantified the density of Brn3+ nuclei in 8 sectors for each 
retina (Fig. 2.1 A), and found that regardless of genotype, there were areas with high and 
low numbers of Brn3+ nuclei (Fig. 2.1B-E), consistent with sectorial downregulation in 
both. We then calculated average densities of Brn3+ nuclei for each retina (Fig. 2.1 F). 
There were similar maximum densities of Brn3+ nuclei in each genotype (Fig. 2.1 F; 
2,400 in DBA/2J and 2,300/mm2 in CX3CR1 null DBA/2J), and similar distribution of 
retinas with varying levels of Brn3 depletion (Fig. 2.1 F), consistent with the varying 
levels of disease severity typically observed in the DBA/2J model. In addition, the 
population mean density of Brn3+ nuclei for each genotype was not significantly 
different (Fig. 2.1F). Therefore, we conclude that at this timepoint, loss of fractalkine 
signaling did not affect the characteristic downregulation of Brn3 that occurs in the 
DBA/2J with age.  
 
Loss of Cx3CR1 increases the number of RGCs with somal  
accumulation of axonal proteins in the DBA/2J retina 
 
Deficits in axonal transport progressively affect RGC axon and somal integrity in 
the DBA/2J (Crish et al., 2010; Dengler-Crish et al., 2014). One marker of disrupted 
axonal transport in DBA/2J retinas is the build-up of phosphorylated neurofilament (pNF; 
medium and heavy) proteins within the proximal axon segment, cell body, and dendrites 
of RGCs (Soto et al., 2008). Within the central retina of both wild type and CX3CR1 
gfp/gfp DBA/2J mice at 10-11 months of age, we found regions with both high and low 
numbers of somal pNF+ RGCs (Fig. 2.2 A-C), consistent with the variable levels of 




Figure 2.1: The density of Brn3+ nuclei does not change with loss of the CX3CR1. 
(A) Confocal image of a representative CX3CR1 null DBA/2J retinal flat mount showing 
the Brn3 immunofluorescence in the central retinal area (1.77mm2). Red boxes depict 
example 0. 06mm2 areas sampled. Sectors of Brn3+ nuclei depletion are apparent in this 
retina. (B,D) Higher magnification images of 0.06 mm2 fields from a DBA/2J flat mount 
retina comparing/contrasting high (C) and low (E) Brn3+ nuclei density. (C,E) Higher 
magnification images of 0.06 mm2 fields from a CX3CR1 null DBA/2J contrasting high 
(B) and low (D) Brn3+ nuclei density. (F) Distribution of Brn3+ nuclei densities per 
retina in DBA/2J (blue) and CX3CR1 null DBA/2J (red). Solid horizontal line indicates 
the population mean, dashed lines indicate 1 standard deviation above and below the 








for each retina, we observed a shift in the distribution of retinas towards a higher density 
of somal pNF+ RGCs with loss of Cx3CR1, which resulted in a statistically significant 
mean increase in somal pNF+ RGCs in Cx3CR1gfp/gfp DBA/2J retinas as compared to 
DBA/2J (Fig. 2.2 D).  
Since somal accumulation of pNF suggests deficits in axonal transport, we 
isolated whole retina mRNA and performed quantitative RT-PCR to determine whether 
there is altered expression of genes involved in transport. Previous work has shown Kif1b 
reduction within sectors of DBA/2J retinas depleted of the retrograde tracer fluorogold 
positive RGCs (Panagis et al., 2010). Compared to DBA/2J, we found that expression of 
the anterograde transport motor Kif1b was significantly reduced in Cx3CR1gfp/gfp DBA/2J 
retinas (25% reduction; n=9 retinas Cx3CR1gfp/gfp DBA/2J n=8 DBA/2J; p<0.05- 
consistent by Student’s t-test).  
 
Loss of CX3CR1 in DBA/2J mice does not exacerbate optic nerve degeneration 
 
RGC degeneration in the DBA/2J model is well characterized within the optic nerve to 
include a progressive loss of RGC axons and a subsequent replacement by glia and 
extracellular matrix (Bosco et al., 2015; John et al., 1998; Libby et al., 2005b; Schlamp et 
al., 2006). To determine whether this optic nerve degeneration is impacted by loss of 
fractalkine signaling, we quantified the extent of non-axonal area using binary masks as 
in Bosco et al. (2015). For DBA/2J and Cx3CR1gfp/gfp DBA/2J genotypes at 10-11 
months, we observed a similar distribution of nerves with relative axonal versus glial 
coverage, ranging from ~10% to above 95% of axon-free area in individual nerves (Fig. 




Figure 2.2: More RGCs have accumulated pNF around the cell soma in retinas with 
disrupted fractalkine signaling.(A) Confocal image of a retinal flat mount 
immunostained for phosphor-neurofilament (pNF) with few somal pNF+ RGCs and 
smooth, fasciculated axons, depicting the sampled central retinal area (1.77mm2) . 
Yellow boxes indicate cells that show pNF accumulated around the cell soma.(B) Higher 
magnification view of an area in A (red box), depicting a cell with accumulated somal 
pNF (yellow box in the bottom right hand corner).(C) Higher magnification of the central 
retinal area from a different retina (same dimensions as in B) depicting many more somal 
pNF+ RGCs (yellow boxes) as well as beaded and de-fasciculated axons.(D) Distribution 
of the number of cells with somal pNF within the central retina in DBA/2J (blue) and 
CX3CR1 null DBA/2J (red). There are significantly more of these cells in CX3CR1 null 
retinas (*: p<.05; Wilcoxon ranked sum test). Solid horizontal line indicates the 
population mean, dashed lines indicate 1 standard deviation above and below the mean. 








Figure 2.3: There is no difference in the amount of gliosis and scarring in the optic 
nerve with loss of fractalkine signaling. (A) Low magnification view of a healthy optic 
nerve cross-section with low gliosis and few dystrophic axonal profiles used for 
subsequent image analysis. (B) Low magnification view of the nerve in A with a binary 
mask including the glia and extracellular matrix indicated in green. The division of the 
area of this mask by the entire optic nerve minus meninges and blood vessels yields the 
% non-axonal area. (C) Low magnification view of a highly affected optic nerve cross-
section with high gliosis and many dystrophic axonal profiles used for subsequent image 
analysis. (D) Low magnification view of the nerve in D with a binary mask including the 
glia and extracellular matrix indicated in green. (E) Distribution of the non-axonal area 
percentages per optic nerve in DBA/2J (blue) and FKNR null DBA/2J (red) showing no 
difference between the genotypes. Horizontal lines indicate the population mean. Error 
bars represent the SEM. Samples that define the limits of 1 standard deviation above and 









area for Cx3CR1gfp/gfp DBA/2J optic nerves as compared to DBA/2J (Fig. 2.3 E). 
Therefore, we conclude that loss of fractalkine signaling did not alter optic nerve 
degeneration on the DBA/2J background at this timepoint within the proximal segment of 
the nerve. 
 
Loss of CX3CR1 increases the number of early declining RGCs 
 
            Loss of fractalkine signaling may be generating newly affected RGCs, impairing  
the clearance of sick RGCs, or both. Therefore, to identify individual RGCs at earlier and 
later stages of decline, we quantified subsets of somal pNF+ RGCs with or without 
nuclear Brn3 expression. While both a reduction in Brn3+ nuclei density and an increase 
in somal pNF+ RGC density occur at 9 months in some DBA/2J animals (Soto et al., 
2008), these readouts have not been examined in combination. We found Brn3+ somal 
pNF+ RGCs and Brn3- somal pNF+ RGCs in both DBA/2J and Cx3CR1gfp/gfp DBA/2J 
genotypes at 10-11 months. This suggests that healthy RGCs express Brn3, but lack 
somal pNF (Brn3+/pNF-), early declining RGCs express Brn3 but accumulate somal pNF 
(Brn3+/pNF+), while RGCs in later stages of decline lose Brn3 expression and retain 
somal pNF (Brn3-/pNF+) before ultimately being eliminated (Fig. 2.4 A-C; Soto et al., 
2008). If there is a failure of clearance of sick RGCs, there should be a selective increase 
in RGCs in the late stage of decline (Brn3-/pNF+). 
We next quantified the density of RGCs in an early stage of decline 
(Brn3+/pNF+) versus late stages of decline (Brn3-/pNF+) for DBA/2J and Cx3CR1gfp/gfp 
DBA/2J retinas. We found a higher proportion of Cx3CR1gfp/gfp DBA/2J retinas that had 
RGCs double positive for Brn3 and somal pNF compared to age-matched DBA/2J mice,  
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and a significant increase in the mean number of RGCs double positive for Brn3 and 
somal pNF (Fig. 2.4 D), suggesting an increase in early declining RGCs. We also 
observed a significant increase in the mean number of RGCs in late stages of decline 
(Brn3-/pNF+), consistent with the overall increase in pNF+ RGCs (Fig. 2.4 E). Since 
there is not a selective increase in this population, we conclude that there is not simply a 
failure to clear sick RGCs in Cx3CR1gfp/gfp DBA/2J retinas. 
We next sought to determine whether somal pNF+ cells were actively dying or 
dead RGCs that had not yet been cleared. We performed immunostaining for cleaved 
caspase 3, and found that none of the pNF+ cells were positive (0 out of 40 somal pNF+ 
RGCs, n = 2 retinas; Fig. 2.5 A-C). In addition, we observed that the nuclei of RGCs 
with somal pNF+ accumulation were not pyknotic (Fig. 2.6 A-C), suggesting they are not 
yet undergoing apoptosis. 
Notably, DBA/2J retinas rarely contained both high density of Brn3+ nuclei and 
high density of Brn3+, somal pNF+ RGCs (Fig. 2.7 B). In contrast, high numbers of 
Brn3+ somal pNF+ RGCs occurred much more frequently in Cx3CR1gfp/gfp DBA/2J 
retinas regardless of Brn3+ nuclei density, and even in retinas with a high overall density 
of Brn3+ nuclei (Fig. 2.7 C). In contrast, with regards to clearance, we found that both 
genotypes had the same percentage (13%) of retinas with below average Brn3+ and 
somal pNF+ density as well as matching optic nerves with above average % non-axonal 
area (Fig. 2.8). Further with respect to clearance, fractalkine has been shown to induce 
the opsonin Mfge8 that stimulates myeloid cells to clear apoptotic neurons (Fuller and 
Van Eldik, 2008). We assessed levels of Mfge8 mRNA in Cx3CR1gfp/gfp DBA/2J (n=3) 




Figure 2.4: Loss of fractalkine signaling results in increased numbers of Brn3+ and 
Brn3- somal pNF+ RGCs. (A) High magnification view of a field of Brn3+ nuclei 
without accumulation of somal pNF. (B) Example of a cell with a Brn3+ nucleus and 
accumulated somal pNF. Orthogonal views in the x-y (bottom) and y-z (side) planes are 
shown. (C) Example of a cell with a Brn3- nucleus and accumulated somal pNF. 
Orthogonal views in the x-y (bottom) and y-z (side) planes are shown. (D) Distribution of 
the number of Brn3+ somal pNF+ cells within the central retina in DBA/2J (blue) and 
CX3CR1 null DBA/2J (red) mice. There are significantly more of these cells in CX3CR1 
null retinas than in the DBA/2J retinas (*: p<.05; Wilcoxon ranked sum test). Solid 
horizontal line are the population mean, dashed lines are 1 standard deviation above and 
below the mean. (E) Distribution of the number of Brn3- somal pNF+ cells within the 
central retina in DBA/2J (blue) and CX3CR1 null DBA/2J (red). There are significantly 
more of these cells in CX3CR1 null retinas (*: p<.05; Wilcoxon ranked sum test). Solid 
horizontal line indicates the population mean, dashed lines indicate 1 standard deviation 






Figure 2.5: Somal pNF+ RGCs are not entering apoptosis (do not express cleaved 
caspase 3). (A-C) Radial cryosections through a CX3CR1 null DBA/2J retina stained for 
phosphorylated neurofilament (white) and cleaved caspase 3(red) with a DAPI nuclear 
counterstain. White arrows indicate somal pNF+ RGCs that are cleaved caspase 3 








Figure 2.6: Somal pNF+ RGCs do not have pyknotic nuclei. (A) Normal appearing 
nuclei from a CX3CR1 null DBA/2J retinal whole mount in the DAPI channel. Arrows 
represent cells in B and C. (B) The same field showing the immunostaining for 
phosphorylated neurofilament. (C) Merge of the two channels showing overlap between 









Figure 2.7: Brn3+ somal pNF+ RGCs accumulate in retinas with higher Brn3+ 
nuclei densities with loss of fractalkine signaling. (A)  Distribution of Brn3+ nuclei 
densities in control DBA/2J (blue line) and CX3CR1 null DBA/2J (red line) retinas with 
retinas sorted in descending order. (B,D) Distribution of Brn3+ somal pNF+ RGCs (B) or 
Brn3- somal pNF+ RGCs (D) amongst control DBA/2J retinas (same retinas as in A, blue 
line), with the total Brn3+ nuclei/mm2 density overlaid. Next to B is an example of a 
Brn3+ somal pNF+ retinas. Next to D is an example of a Brn3- somal pNF+ RGC. (C,E) 
Distribution of Brn3+ somal pNF+ RGCs (C) or Brn3- somal pNF+ RGCs (E) amongst 
CX3CR1 null DBA/2J retinas (same retinas as in A, red line), with the total Brn3+ 











Figure 2.8: There are similar percentages of samples with markers of RGC 
clearance (low Brn3+ nuclei and somal pNF+ RGC density and a high % non-
axonal area in the optic nerve) with loss of fractalkine signaling. (A) Distribution of 
Brn3+ nuclei densities in control DBA/2J (blue line) and CX3CR1 null DBA/2J (red line) 
sorted in descending order with the % non-axonal area in the corresponding optic nerve 
for control DBA/2J (green line) and CX3CR1 null DBA/2J (purple line) overlaid for each 
sample. Samples depicted in B-D and E-G are shown on the curve. (B-D) Representative 
example of an optic nerve with extensive scarring (B) with a matching retina depleted of 
Brn3+ nuclei (C) and few somal pNF+ RGCs (D). (E-G) Representative example of an 
optic nerve with little scarring (E) with a matching retina depleted of Brn3+ nuclei (F) 
and few somal pNF+ RGCs (G). Note the increased number of dystrophic axonal profiles 
within optic nerves that have a low density of Brn3+ nuclei in the retina. Amoeboid 








these findings suggest that loss of fractalkine signaling is amplifying the generation of 
dystrophic RGCs rather than impairing their clearance.   
 
There are more infiltrating macrophages in Cx3CR1gfp/gfp DBA/2J retinas 
 
Given that fractalkine signaling regulates many myeloid cell responses, including 
microglial activation, distribution, and recruitment of peripheral monocytes (Cardona et 
al., 2006; Wolf et al., 2013), we examined how loss of fractalkine signaling affected 
myeloid cell activation in terms of morphology, number, and levels of the activation 
associated gene, Iba1 (Inman and Horner, 2007) in CX3CR1 null DBA/2J mice.  
We observed three distinct morphological subtypes of Iba1+ cells within the retina: cells 
with a small soma and many branches (“branched”), cells with two main branches on 
polar opposite sides typically outlining blood vessels (“perivascular”), and spherical cells 
with no branches (“amoeboid”) (Fig. 2.9 A-C). We presume these cell subtypes to 
respectively represent resident microglia, perivascular macrophages, and either 
infiltrating macrophages or highly activated resident microglia. We found no change in 
the numbers of branched Iba1+ cells (Fig. 2.9 D-F) within Cx3CR1gfp/gfp DBA/2J retinas, 
suggesting no change in the resident microglia population. We observed a trend towards 
significance (p< 0.1) in the number of perivascular cells, but quantified a significant 
increase in the number of amoeboid Iba1+ cells. We found equal levels of Iba1 mRNA 
between the genotypes by qRT-PCR, suggesting no significant changes in the levels of 
myeloid cell activation. 
To determine whether the amoeboid Iba1+ cells were infiltrating macrophages, 




Figure 2.9: Loss of fractalkine signaling results in greater numbers of amoeboid 
shaped Iba1+ cells. (A) Low magnification view of an entire retinal flat mount that was 
sampled for Iba1+ cells showing amoeboid morphology. Blood vessels (traced) were 
excluded from analysis. (B) Higher magnification view of the area indicated in A 
demonstrating the 3 categories of shapes for Iba1+ cells. The white circle depicts a cell 
with amoeboid morphology , the green box depicts a cell with branched morphology, and 
the orange box indicates a perivascular-shaped Iba1+ cell. (C) Low magnification image 
of the central retina (1.77mm2) depicting the area sampled for branched and perivascular 
shaped Iba1+ cells excluding the optic nerve head (marked by an asterisk and traced by 
the red circle). (D-F) Distribution of the number of branched (D), perivascular (E), and 
amoeboid shaped Iba1+ cells (F) within the central retina in DBA/2J (blue) and CX3CR1 
null DBA/2J (red). There are significantly more amoeboid Iba1+ cells (*: p<.05; 
Wilcoxon ranked sum test) in CX3CR1 null retinas. There are no statistically significant 
changes in the numbers of branched or perivascular Iba1+ cells (p<.3 and p<.1 
respectively). Horizontal lines indicate the population mean. Error bars represent the 
samples that define the limits of 1 standard deviation above and below the mean are 
indicated by bold outlines. Scale bars: 500 um (A), 50um (B), 250um (C) 
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were exclusively located in the nerve fiber layer (Fig. 2.10 A), as reported for infiltrating 
macrophages in retinal injury paradigms (Garcia-Valenzuela and Sharma, 1999) and 
macrophages that patrol the vitreous body (Vagaja et al., 2012). However, we wanted 
tomore definitively determine if these cells were infiltrating macrophages, so we 
immunostained for the peripheral macrophage marker CCR2 (Saederup et al., 2010). We 
determined that the amoeboid shaped Iba1+ cells stained positive for the peripheral 
macrophage marker CCR2 in whole mounts from control DBA/2J retinas (Fig. 2.10 B) 
and in cryosections from CX3CR1 null DBA/2J retinas (Fig. 2.10 C&D). 
To determine whether the amoeboid Iba1+ cells were involved in driving the 
enhanced RGC pathology that we observed in Cx3CR1gfp/gfp DBA/2J retinas, we 
examined whether numbers of amoeboid Iba1+ cells correlated with RGC pathology in 
the retina. Surprisingly, we found a poor correlation between numbers and distribution of 
spherical Iba1+ cells and density of either Brn3+ nuclei or somal pNF+ RGCs in both 
DBA/2J and Cx3CR1gfp/gfp DBA/2J retinas (Fig. 2.10 E). Together, our data support a 
model in which loss of fractalkine signaling primarily increased macrophage infiltration 
in aged retinas rather than increasing resident microglia activation, consistent with the 
findings of Sennlaub et al. (2013). Surprisingly, the lack of correlation between these 
peripherally derived macrophages and RGC pathology suggests that the blood-derived 
monocytes may not be driving the differences in RGC pathology that we detected in 









Figure 2.10: Amoeboid Iba1+ cells are peripherally derived macrophages but they 
do not correlate with RGC pathology in either genotype. (A) Amoeboid Iba1+ cells 
localize to the neurofibrillary layer. Volume view of CX3CR1 null DBA/2J retinal whole 
mount stained for the axonal marker pNF and the microglia/macrophage marker Iba1. 
Orthogonal views shown below and to the right. Amoeboid Iba1+ cells showed non-
specific reactivity with the donkey anti-mouse secondary antibody used to detect pNF. 
(B) Single z-plane from a control DBA/2J retinal whole mount immunostained for the 
peripheral macrophage marker CCR2 (red) and Iba1. The amoeboid shaped Iba1+ cells 
are positive for CCR2 while branched Iba1+ cells are negative. (C & D) Single z-plane of 
a radial section from a CX3CR1 null DBA/2J retina immunostained for the peripheral 
macrophage marker CCR2 (red) and showing gfp expressed by cells expressing the 
CX3CR1 gene. Dapi (white) denotes the ganglion cell layer (GCL). Amoeboid 
CX3CR1+ cells above the GCL are CCR2 positive. (E) There is no correlation between 
the number of amoeboid Iba1+ cells and either the density of Brn3+ nuclei or somal 
pNF+ RGCs, regardless of genotype. R2 value for amoeboid Iba1+ cells vs Brn3+ nuclei 
density (top) is .32 and .14 for DBA/2J and CX3CR1 null DBA/2J mice, R2 value density 
of somal pNF+ cells (middle) is .05 and .08, R2 value for % non-axonal area (not shown) 








We found that loss of CX3CR1 in the DBA/2J background had a selective effect 
on RGC somal integrity, likely due to deficient axonal transport, but did not affect other 
aspects of RGC neurodegeneration, including loss of gene transcription or optic nerve 
histopathology. These changes were concomitant with increased infiltration of CCR2+  
peripheral macrophages but not myeloid activation overall, since levels of Iba1 mRNA 
were unaffected. This study reveals a selective role for FKN signaling on one aspect of 
RGC degeneration, and demonstrates that loss of FKN signaling primarily increased 
macrophage infiltration.   
 
Loss of CX3CR1 affects compartmentalized RGC degeneration 
 
Our compartmental approach to analyze RGC neurodegeneration in the DBA/2J 
model of chronic glaucoma revealed that disruption of CX3CR1 has selective effects on 
RGC axonal transport that are uncoupled from other RGC degenerative changes. While 
decline of RGC axons has clearly been shown to be crucial in degeneration (Howell et 
al., 2007), degenerative changes in other compartments also contribute to RGC demise 
(Fernandes et al., 2014). Our findings suggest that distinct mechanisms may drive these 
diverse degenerative changes in RGCs, and implicate myeloid cells specifically in 
modulating the decline of axon transport that is a hallmark of many neurodegenerative 
diseases.   
It is unknown whether during the course of neurodegeneration somal decline and 
axonal degeneration are linked. Our findings suggest that these events can be uncoupled 
since we were able to find retinas severely depleted of Brn3+ nuclei that nonetheless had 
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few somal pNF+ RGCs, and an optic nerve with relatively intact axons and little gliosis 
(Fig. 2.8). The existence of such samples suggests very important pathological events are 
taking place in the retina prior to histologic degeneration of the optic nerve. These 
findings suggest that in the absence of being able to derail the initiating event in 
neurodegeneration, treatment directed to multiple neuronal compartments may be 
necessary to delay or halt progression. 
Interestingly, loss of CX3CR1 is not the only instance of somal accumulation of 
pNF in RGCs being uncoupled from optic nerve degeneration. Another example is the 
wabbler-lethal mutant mouse that has a loss of function mutation in the phosphatidyl-
serine flippase, Atp8a2, which is involved in apoptosis and vesicle trafficking (van der 
Mark et al., 2013; Zhu et al., 2012). This mutant mouse shows disrupted axonal transport 
with an increase in RGCs with somal pNF, without increased damage to the optic nerve. 
We found a significant (15%) reduction in mRNA levels of Atp8a2 in our CX3CR1 null 
DBA/2J retinas versus the control DBA/2J retinas, suggesting that this pathway may be 
in part responsible for reducing RGC axonal transport. These results raise the question of 
whether exposed phosphatidyl-serine signaling to receptors on microglia or macrophages 
affects RGC degeneration, or if a cell autonomous role in membrane fluidity affects 
axonal transport. 
An early step in the decline of RGCs is downregulation of RGC genes, such as the 
transcription factor family Brn3 (Domenici et al., 2014; Welsbie et al., 2013). In our 
study, Brn3 downregulation was evident in both DBA/2J and CX3CR1 null DBA/2J 
retinas, but we did not see a difference in the number of Brn3 positive nuclei, either in the 
central retina or in a set of 35 control and 40 CX3CR1 null DBA/2Js sampled throughout 
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the retina (data not shown). This suggests that numbers of RGCs were not significantly 
different with loss of CX3CR1 in a chronic disease setting, and that this aspect of early 
RGC decline is not influenced by CX3CR1 signaling in myeloid cells. In contrast, Wang 
et al. (2014) found significant reductions in beta tubulin III labeled RGCs in a transient 
ocular hypertension model of glaucoma. Although different markers of RGCs were 
assessed, it is possible that CX3CR1 signaling has different effects in an acute injury 
versus chronic model of RGC degeneration. It is unknown whether similar mechanisms 
are driving RGC decline in these distinct models, but our findings suggest differential 
roles for myeloid cells. In general, it is unclear whether the myeloid system is 
phenotypically similar between acute and chronic models of neurodegeneration.    
 
Potential roles of infiltrating macrophages and resident microglia  
in neurodegeneration 
 
Since Cx3CR1 in the retina is selectively expressed by myeloid cells, our findings 
indicate that alterations in these cells drove a selective increase in somal pNF+ RGCs. 
FKN signaling has been assumed to be a brake on microglial activation in many models 
of neurodegeneration (Bhaskar et al., 2010; Cardona et al., 2006; Wang et al., 2014). 
However, we found that the activation of the presumed resident microglia (branched 
Iba1+ cells) remained unchanged in terms of morphology and Iba1 mRNA levels with 
loss of CX3CR1. However, other aspects of microglia function may be affected. For 
example, CX3CR1 null microglia have been noted to more slowly remodel their 
processes (Liang et al., 2009), suggesting functional impairment. Whether there is a 
functional change in resident microglia in our model remains unclear. 
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Our findings rather suggest that some of the previously reported effects on 
microglia activation and neurodegeneration may be due to enhanced macrophage 
infiltration. Increased CCR2+ macrophage infiltration on a CX3CR1 null background is 
consistent with the findings of (Sennlaub et al., 2013) in age and light damage models of 
subretinal inflammation that clearly showed a pathogenic role for these infiltrating 
macrophages. While we did not directly test this possibility, the lack of correlation 
between numbers of these macrophages and measured RGC pathology suggests that 
infiltrating macrophages may be involved in other aspects of glaucoma. Since 
macrophages have been implicated in RGC regeneration (Cui et al., 2009), it is entirely 
possible that their role in RGC compartmentalized degeneration may be either beneficial 
or detrimental. Whatever the mechanism, the data presented here suggest that myeloid 
dysfunction may contribute to the impaired axonal transport seen early in many 
neurodegenerative diseases (Morfini et al., 2009). 
All together, this study demonstrates the value in examining neurodegeneration in 
a compartmentalized manner and determining the lineages of myeloid cells involved. 
There is a longstanding question in the literature as to what extent a toxic gain of function 
in myeloid cells, a loss of myeloid supportive functions, or both contribute to 
neurodegeneration (Rivest, 2009; Streit and Xue, 2014). Perhaps myeloid lineage specific 
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Alejandra Bosco originally conceived of the idea to use in vivo confocal 
microscopy to monitor microglial activation and relate it to later optic nerve degeneration 
as well as the idea to use binary masks of glia and extracellular matrix as a proxy for 
axon loss in the optic nerve. I was crucial to this process by generating these masks and 
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gathering the data that was critical in establishing a strong correlation between early 
microglial activation and later optic nerve degeneration (Fig. 3.5). I was also instrumental 
in validating the use of CD169/Sialoadhesin as a marker of infiltrating macrophages in 
LPS intravitreally injected tissue as well as aged DBA/2J mice (Fig 3.6). I also quantified 
the co-localization between CD169 and the GFP expression marking all myeloid cells in 
the CX3CR1 gfp/+ DBA/2J mice (Fig. 3.6). All in all I generated and quantified key data 
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Neurodegeneration severity can be predicted from early microglia
alterations monitored in vivo in a mouse model of chronic
glaucoma
Alejandra Bosco1,*, Cesar O. Romero1, Kevin T. Breen1, Alexis A. Chagovetz2, Michael R. Steele1,
Balamurali K. Ambati3 and Monica L. Vetter1
ABSTRACT
Microglia serve key homeostatic roles, and respond to neuronal
perturbation and decline with a high spatiotemporal resolution. The
course of all chronic CNS pathologies is thus paralleled by local
microgliosis and microglia activation, which begin at early stages of
the disease. However, the possibility of using live monitoring of
microglia during early disease progression to predict the severity of
neurodegeneration has not been explored. Because the retina allows
live tracking of fluorescent microglia in their intact niche, here we
investigated their early changes in relation to later optic nerve
neurodegeneration. To achieve this, we used the DBA/2J mouse
model of inherited glaucoma, which develops progressive retinal
ganglion cell degeneration of variable severity during aging, and
represents a useful model to study pathogenic mechanisms of retinal
ganglion cell decline that are similar to those in human glaucoma. We
imagedCX3CR1+/GFPmicroglial cells in vivo at ages ranging from 1 to
5 months by confocal scanning laser ophthalmoscopy (cSLO) and
quantified cell density and morphological activation. We detected
early microgliosis at the optic nerve head (ONH), where axonopathy
first manifests, and could track attenuation of this microgliosis
induced by minocycline. We also observed heterogeneous and
dynamic patterns of early microglia activation in the retina. When the
same animals were aged and analyzed for the severity of optic nerve
pathology at 10 months of age, we found a strong correlation with the
levels of ONHmicrogliosis at 3 to 4 months. Our findings indicate that
live imaging and monitoring the time course and levels of early retinal
microgliosis and microglia activation in glaucoma could serve as
indicators of future neurodegeneration severity.
KEY WORDS: Microglia activation, Microgliosis, Retinal
ganglion cells, Confocal ophthalmoscopy, Live image analysis,
Cx3cr1GFP/+ DBA/2J
INTRODUCTION
The ability to detect and monitor a neurodegenerative disease
soon after its onset and to anticipate its future progression is a
fundamental step towards uncovering early pathogenic mechanisms
and developing targeted therapies. Such an early diagnostic and
prognostic strategy depends on the detection of cellular and/or
molecular markers dynamically linked with the pathogenic process of
neurodegeneration. Growing evidence indicates that a wide range of
neurodegenerative diseases are associated with innate immune
responses from microglia, and in certain contexts, from recruitment
of blood-derivedmonocytes ormacrophages (Amoret al., 2014, 2010;
Block et al., 2007; Cunningham, 2013; Perry and Teeling, 2013).
Microglia are long-lived myeloid cells that stably inhabit the adult
CNS within parenchymal and perivascular niches (Kettenmann et al.,
2011; Lawson et al., 1990, 1992; Prinz et al., 2011). Functionally, they
constantly interact with surrounding neurons, blood-brain barrier cells
and other glia (Davalos et al., 2005; Nimmerjahn et al., 2005;
Ransohoff and Cardona, 2010; Ransohoff and Perry, 2009; Tremblay
et al., 2010; Wake et al., 2009). Stress or damage to surrounding cells
causes rapid microglial activation (Kettenmann et al., 2011;
Kreutzberg, 1996), as identified by complex molecular, functional
and cellular changes, as well as microgliosis, which refers to the
expansion of microglial cell numbers by local self-renewal and/or
recruitment of monocytes and/or macrophages from the blood-stream
or, potentially, from latent progenitors (Ajami et al., 2007; Elmore et al.,
2014; Lawson et al., 1992; Ransohoff and Cardona, 2010; Solomon
et al., 2006; Streit et al., 1999). Thus,microglia, as ubiquitous, dynamic
sensors ofCNSdamage anddyshomeostasis, are ideally suited todetect
and indicate the progression of pathogenic processes.
Microgliosis and microglial activation mirror the course of
neurodegeneration in both clinical and animal model studies of
multiple diseases, such as Alzheimer’s, Parkinson’s and
Huntington’s disease (Ajami et al., 2011; Maeda et al., 2011;
Ouchi et al., 2005; Sapp et al., 2001). Moreover, live imaging
studies that have monitored microglial alterations have found
evidence for their involvement at preclinical disease stages (Ajami
et al., 2011; Davalos et al., 2012; Fuhrmann et al., 2010; Maeda
et al., 2011; Ouchi et al., 2005; Sapp et al., 2001). Thus, CNS-
resident microglia and infiltrating monocytes and macrophages are
emerging as promising sensitive indicators of neuronal decline;
however, their ability to predict later disease is not well defined,
particularly at early stages of disease. Detection of microglial
distribution and activation by molecular imaging of the brain using
positron emission tomography has underscored the relevance of
microglial activation as a relevant biomarker of disease in multiple
neurological and psychiatric conditions (Jacobs and Tavitian,
2012; Politis et al., 2012; Venneti et al., 2013). The actual behavior
of microglia at the cellular level during health, acute injury and
chronic neurodegeneration has been studied in animal models over
the course of minutes, and for up to 4 months, by direct observation
of fluorescently labeled cells using two-photon confocal imaging
of the brain, retina and spinal cord (Davalos et al., 2005, 2012;Received 14 October 2014; Accepted 26 February 2015
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Dibaj et al., 2011; Evans et al., 2014; Fuhrmann et al., 2010;
Kozlowski and Weimer, 2012; Nayak et al., 2012; Nimmerjahn
et al., 2005; Tremblay et al., 2010; Wake et al., 2009), and by
confocal scanning laser ophthalmoscopy (cSLO) of the retina
(Maeda et al., 2014; Seeliger et al., 2005). Given that in vivo
imaging of the retina using cSLO is non-invasive, this technique
has been used to directly visualize GFP-labeled retinal microglia in
the mouse eye, and in some cases to monitor changes in a single
animal over a limited period of time (Alt et al., 2012; Eter et al.,
2008; Liu et al., 2012; Paques et al., 2010, 2006). Although these
previous studies have detected changes in microgliosis in response
to acute injury, what remains to be determined is whether this
approach can be used in a chronic, progressive, age-related model
of retinal disease to detect and quantify early changes in microglia
that would predict the later course of neurodegeneration.
A relevant neurodegenerative disease of the retina with
unresolved pathogenesis is glaucoma. The ability to detect and
monitor glaucoma at early stages would offer the potential for early
intervention in this disease. As a model of inherited, age-dependent
glaucoma, we use DBA/2J mice, which like human patients
undergo slow, asynchronous and chronic decline and loss of retinal
ganglion cells (RGCs) and their axons in the optic nerve and retina
(Casson et al., 2012; Nickells et al., 2012; Quigley, 1999, 2011;
Weinreb and Khaw, 2004). Axonopathy first manifests at the optic
nerve head (ONH), where unmyelinated axons exit the eye, and
progressively expands across asymmetrical areas of the retina
(Buckingham et al., 2008; Howell et al., 2007a; Inman et al., 2006;
Schlamp et al., 2006; Soto et al., 2008), offering remarkable spatial
resolution to track disease progression. Microglia activation has
been associated with human glaucoma (Gramlich et al., 2013;
Neufeld, 1999), and early alterations in retinal microglia, and
potentially monocyte infiltration, precede detectable neuronal
pathology in DBA/2J mice (Bosco et al., 2012, 2011; Fan et al.,
2010; Howell et al., 2011). However, a predictive link between early
microglia and/or peripheral monocyte alterations and later disease
progression has not been defined.
To address this, our current approach took advantage of the
remarkable variability of neurodegeneration severity across DBA/
2J eyes (Anderson et al., 2001; Chang et al., 1999). To track retinal
and ONH microglia and recruited monocytes in vivo with single-
cell resolution, we generated DBA/2J mice carrying the microglia
and monocyte reporter CX3CR1-GFP and applied recently
optimized cSLO imaging and automated morphometric cell
analysis to quantitatively monitor microgliosis and microglia
activation from 1 to 5 months of age in a large cohort of young
mice (Bosco et al., 2015). After allowing these same mice to age,
we analyzed optic nerve pathology ex vivo. We provide evidence
that microglial alterations are selectively detectable in eyes that
progress to glaucoma at later stages, and establish that early
microgliosis has a strong correlation with the severity of optic
nerve degeneration. Taken together, these findings provide the first
evidence that in vivo monitoring of the time course and dynamics
of early microglia might serve as sensitive predictors of late chronic
neurodegeneration.
RESULTS
Microglia can be visualized and tracked in vivo throughout
the retina and ONH preceding neurodegeneration in
Cx3cr1GFP/+ DBA/2J mice
To allow the long-termmonitoring and quantification of the kinetics
of microgliosis and microglia activation during chronic glaucoma in
live DBA/2J mice, we performed backcrossing to generate a
substrain carrying a knock-in allele that expresses GFP under the
control of the fractalkine receptor promoter (Cx3cr1; Jung et al.,
2000). This reporter not only labels resident microglia but also
peripheral monocytes and macrophages that can infiltrate the
diseased or injured CNS (Ajami et al., 2011; Broux et al., 2012;
Jung et al., 2000). Using cSLO inCx3cr1GFP/+DBA/2J mice aged 1
to 5months, we imaged individual eyes to track GFP+ cells localized
to the ONH and central retina (Bosco et al., 2015). At monthly
intervals, we collected single and multiple xy-point confocal images
centered on the optic disc in fundus images, and spanning
approximately the central 1.5 mm or 1.5×3 to 4 mm of each
retina, respectively, and its inner 30 to 40 µm in depth (Fig. 1A,B;
supplementary material Fig. S1A). These live confocal images
provided enough cellular resolution to visualize cell somata, and in
some cases arbor dimensions (Fig. 1C), and to recognize three
distinct subsets of GFP+ cells of microglial or macrophage origin:




diseases. Early detection is key for slowing or halting neuronal decline
and loss, underscoring the importance of defining reliable indicators of
diseaseonset andprogression.Thecourseof neurodegeneration ismirrored
by innate immune responses of CNS-resident microglia and infiltrating
monocytes. Live imaging studies have detected early microglial alterations
in animal models and humans, suggesting that they have potential value
as sensitive indicators of disease progression. However, whether the
early changes of innate immune cells are related to and can predict later
neurodegeneration is unknown. Glaucoma results in progressive
neurodegeneration of retinal ganglion cells (RGCs) and their axons in the
optic nerve and retina. The disease is mostly asymptomatic at early stages
and is detectable only once vision is irreversibly compromised. Despite
this, the possibility of live monitoring retinal microglia to predict future
neurodegeneration severity in glaucoma has not yet been explored.
Confocal ophthalmoscopy (cSLO) allows for direct and repeated
visualization and tracking of the microglial alterations that precede
neurodegeneration in the intact retinal niche.
Results
Here, the authors use a mouse model of inherited glaucoma that, as in
the human condition, develops age-dependent and variably severe
neurodegeneration, coupled with innate immune responses. To assess
the kinetics of early microgliosis (accumulation of microglia at the site of
injury) and microglia activation, they used a DBA/2J reporter substrain in
which microglia and infiltrating monocytes express green fluorescent
protein (GFP) under the control of the fractalkine receptor locus (Cx3cr1),
and imaged young mice at 1 to 5 months of age by cSLO to monitor early
microglial changes. The authors then aged the mice to 10 months and
analyzed optic nerve pathology ex vivo. Across individual eyes, live
images collected at pre-pathological ages revealed dynamic patterns of
retinal microglial activation and an unexpected diversity in the levels of
microgliosis at the optic nerve head (ONH), which was attenuated by
minocycline. Notably, they identified a significant correlation between
early microgliosis at the ONH and the late severity of nerve pathology.
Implications and future directions
This study establishes microglia as indicators and early predictors of late
optic nerve degeneration in a model of chronic glaucoma. This live
imaging approach is the first to visualize, quantify and monitor microglial
cellular changes during early stages of a neurodegenerative disease.
The findings are broadly relevant to the field of neurodegeneration
because they link microglial changes to future disease progression.
Moreover, this study developed a non-invasive strategy to monitor visual
biomarkers that is applicable to tracking and managing glaucoma and
other chronic CNS diseases that affect RGCs.
444






















300 cells), (2) a central cluster of microglia and/or blood-derived
monocytes or macrophages localized to the ONH area, and (3)
perivascular cells radiating from the ONH (Fig. 1B). We compared
live and ex vivo confocal images of individual eyes collected less
than 3 days apart, and confirmed that cSLO detects individual GFP+
cells throughout the inner retinal layers (supplementary material
Fig. S1B-E). Therefore, cSLO live imaging allows the tracking of
cellular changes in retinal microglia and infiltrating monocytes that
are localized adjacent to RGC somata, dendrites and unmyelinated
axons across the inner retinal surface and ONH (Bosco et al., 2011).
We applied cell segmentation and morphometry to cSLO images
of the central 1.5-1.7 mm2of retina to identify activated parenchymal
microglia (Bosco et al., 2015). Briefly, using intensity-threshold-
based morphometric analysis, we identified activated parenchymal
microglia as cells with large somal areas (>50-60 µm2) and a few
short processes, and non-activated parenchymal and perivascular
microglia as cells with somata that were 2-3 times smaller in area and
had visibly extensive and complex arbors. Microglial soma size has
been shown to increasewith Iba1 upregulation, and provides ametric
to determine the activation status of individual GFP+ cells in live
image analysis (Bosco et al., 2008; Kozlowski and Weimer, 2012).
In sequential images of the same retinas collected at 3 and 4 months
of age, we mapped and quantified numbers of activated and non-
activated microglia across eight sectors radiating from the optic disc
(supplementary material Fig. S2A,B), and at each age detected
variable numbers of activated microglia between sectors and retinas,
which were uncoupled from the concurrent changes in total GFP+
cell density (supplementary material Fig. S2B,C). For most of the
individual retinas monitored over 2 months, numbers and
distribution of GFP+ cells and activated microglia were dynamic
(supplementary material Fig. S2C, left), although some retinas
maintained relatively static levels and/or patterns of activation
(supplementary material Fig. S2C, right).
Induced changes in retinal microgliosis can be monitored
over time by cSLO
Previous live imaging studies of retinal GFP+ microglia and
macrophages have tracked changes in cell numbers in response to
acute optic nerve injury (Eter et al., 2008; Liu et al., 2012). To
determine the sensitivity of our methods to detect longitudinal
changes in microgliosis in a chronic model, we induced a subtle
reduction in microgliosis during early disease progression by
treating young DBA/2J mice with minocycline, which we have
previously shown decreases both the number and activated
phenotype of retinal microglia and/or peripheral monocytes
(Bosco et al., 2008). First, we identified a subset of 2-month-old
Fig. 1. In vivomonthly imaging of retinal and ONH microglia and/or peripheral monocytes during early stages of chronic glaucoma. (A) Monthly cSLO
image sequence of the same eye, showing GFP+ cells within∼2 mm2 of retina around the ONH (circle) in youngCx3cr1GFP/+DBA/2Jmice. The original greyscale
was inverted to improve observation. (B) Multipoint cSLO image spanning approximately one third of the same retinawhen themousewas 5months old. There is a
cluster of GFP-labeled cells localized to the ONH (circle), and radial rows of perivascular cells with bipolar shape along vessels (arrows), which interrupt
the regular mosaic of parenchymal microglia. Live infrared fundus images of vasculature and optic disc (inset) were acquired for each fluorescence image, to
facilitate the alignment of sequential images. (C) High-magnification view of parenchymal and perivascular GFP+ cells (arrows). For parenchymal cells, the
microglial soma size is readily identifiable, whereas process number and length are better resolved in larger cells. Scale bars: 250 µm (A,B), 50 µm (C).
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mice with relatively high ONHmicrogliosis by cSLO imaging, then
administered systemic minocycline (120 mg/kg body weight for
6 weeks), and collected cSLO images after treatment at 4 months of
age (Fig. 2A). The quantification of GFP+ cell numbers within the
ONH area showed that there were significant decreases in cell
clustering in the treated eyes (P<0.05, n=9 eyes, Student’s t-test;
Fig. 2B). The ONH GFP+ cells also displayed a manifest reduction
in Iba1 expression relative to untreated eyes (Fig. 2C), consistent
with the microglial deactivation reported for minocycline in this
model (Bosco et al., 2008). Thus, live retinal imaging can track an
induced attenuation in early microgliosis.
Young DBA/2J mice show highly variable levels of ONH
microgliosis
Previous studies have established that DBA/2J mice typically lack
histologically detectable retinal and optic nerve pathology in the first
6 months of age (John et al., 1998); however, young mice show
clustering, activation and proliferation of Iba1+ microglia and/or
peripheral monocytes at the ONH in some eyes (Bosco et al., 2012,
2011). Given that the age of glaucoma onset and progression are
diverse in thismodel (Anderson et al., 2001;Chang et al., 1999), itwas
unclear whether these early microglia and infiltrating monocyte
changes were linked to later neurodegeneration. To track the presence
and levels of early ONH microgliosis prior to RGC degeneration, we
analyzed cSLO retinal images collected between 1 and 5 months of
age with preferential imaging at 3 months of age (Fig. 3A;
supplementary material Fig. S1), when microgliosis in the DBA/2J
retina peaks (Bosco et al., 2011). We detected a significant increase in
the mean number of GFP+ cells localized to the ONH at 3 months
(P<0.01, n=19 to 59 eyes; Student’s t-test), which persisted through
5 months (Fig. 3B), in agreement with ex vivo studies (Bosco et al.,
2011). Furthermore, statistical analysis controlling for the potential
effect of repeated imaging on individual eyes confirmed this result
(linear mixed model; http://CRAN.R-project.org/package=lme4;
Fig. 2. Induced decreases in local microgliosis are detectable by live imaging. (A) Live cSLO images of the same ONH before and after oral minocycline
treatment (mousewas 2 and 4months old, respectively) showing a reduction in GFP+ cell clustering, compared to an age-matched untreated control representing
moderate microgliosis. (B) Total number of cells per ONH at 2 and 4 months of age (n=9 eyes represented by circles) plotted before and after minocycline
treatment showing a significant mean reduction post-treatment (*P<0.05; Student’s t-test). Bars indicate mean±s.e.m. at each age (16.9±1.65 cells per 0.05 mm2
and 13±1.53, respectively). The graph to the right depicts with lines the drop in microgliosis in 6/9 individual ONHs. (C) Ex vivo immunostaining of the same
4-month-old ONHs shown in A revealing that there is a noticeable downregulation of Iba1 expression, but not of GFP, after minocycline treatment, as visible in
the single-channel view of Iba1 and its pseudocolor coding by expression intensity. Each image shows a maximum intensity projection of 50 µm and represents
the ONH area. Scale bars: 250 µm (A), 25 µm (C).
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P<0.0001), demonstrating that the effect of repeated observations
on individual eyes is negligible (P=0.0942). Notably, we observed
that eyes of the same age displayed widely variable GFP+ cell
density, ranging from 5 to 30 cells per 0.05 mm2.
Early ONH microgliosis precedes late optic nerve
degeneration
The diversity in levels of ONH microgliosis raised the question
as to whether it reflects early, differential progression towards
disease in a subset of eyes. To address this possibility, we
assessed optic nerve pathology ex vivo in the same eyes at
10 months of age, when glaucomatous degeneration is evident in
many DBA/2J mice (Fig. 4A-C). Glaucoma onset and the
severity of neurodegeneration are highly variable in DBA/2J
mice, thus axonal pathology can manifest with variable levels
and distribution in individual optic nerves (Buckingham et al.,
2008; Howell et al., 2007a; Inman et al., 2006; Jakobs et al.,
2005; John et al., 1998; Libby et al., 2005; Schlamp et al., 2006;
Soto et al., 2008). Using an established damage scoring system
(Anderson et al., 2005; Howell et al., 2007a; Libby et al., 2005),
high-resolution light microscopy images of 1-µm-thick cross-
sections of individual nerves were categorized at one of three
levels of damage based on qualitative parameters of pathology
(Fig. 4C; see Materials and Methods). Next, the numbers of
GFP+ cells per ONH at 1 through to 5 months of age were plotted
for nerves in each damage category (Fig. 4D). All 1-month-old
mice showed similarly low GFP+ cell densities in the ONH, but
this analysis revealed a distinct trend to increase from 2 to 5
months of age, where nerves with severe late damage showed the
highest levels of microgliosis, whereas nerves with moderate
damage were preceded by more intermediate and variable levels
of microgliosis. A Kruskal–Wallis rank ordered test showed
that the median GFP+ cell density per ONH for each level of
severity of optic nerve pathology was significantly different at
3 months (χ2=07.84, P=0.0199) and 4 months of age (χ2=16.27,
P=0.0003), and marginally significant at 5 months of age
(Fig. 4E). This initial analysis shows a significant relationship
between the early number of GFP-labeled cells at the ONH and
the extent of late optic nerve degeneration.
Early ONH microgliosis correlates with future optic nerve
pathology
To thoroughly define the correlation between ONH microgliosis at a
young age and the susceptibility to develop glaucoma at an older age,
we established a quantitative measure of optic nerve pathology based
on the magnitude of gliosis and gliotic scaring associated with nerve
degeneration (Crish et al., 2010; Libby et al., 2005; Schlamp et al.,
2006). It iswell documented that as axons are lost in the optic nerve, the
area is replaced by reactive glia (hypertrophic and proliferative), and by
a glial scar at the end stages of neurodegeneration (Burda and
Sofroniew, 2014; Crish et al., 2010; Dai et al., 2012; Hernandez, 2000;
Lye-Barthel et al., 2013; Qu and Jakobs, 2013; Sofroniew, 2009; Son
et al., 2010; Sun and Jakobs, 2012; Sun et al., 2009). Therefore, the
reduction of the non-axonal area at the expense of expanding glial
territories in late stages of glaucoma was used as readout of nerve
pathology severity. For this, we applied threshold-based segmentation
of glial cells and scar tissue to high-resolution light images of entire
optic nerve sections from 10-month-old mice (Fig. 5A, see Materials
and Methods). Consistent with the variability in glaucoma onset and
progression in DBA/2J mice, individual optic nerves showed large
variability in the relative area occupied by glial cells or scar, whichwas
consistently increased in nerves with widespread axonal damage and
loss. According to the quantification of non-axonal area, individual
Cx3cr1GFP/+ DBA/2J nerves were classified as healthy if their total
glial territoryoccupied less than 20%of thenerve,which is comparable
to Gpnmb+/SjJ DBA/2J nerves (A.B., K.T.B., S.R.A., M.R.S., D.J.C.
andM.L.V., unpublished data), the congenic control strain that carry a
wild-type Gpnmb allele and do not undergo RGC degeneration
(Howell et al., 2007b). Glaucomatous nerves with increased glial
coverage were classified as having medium (20-40%) or high (>40%)
gliosis (Fig. 5B). To confirm this classification, we compared the
average glial area in each category and observed a significant increase
from low to medium and then to high gliosis (P<0.001, n=41 eyes;
Student’s t-test). We thus used the expansion of gliosis and gliotic scar
throughout areas devoid of RGC axons as a novel and objective
measure of nerve degeneration severity.
Plotting the levels of early ONH microgliosis versus the
magnitude of late nerve gliosis for each individual eye (Fig. 5C)
revealed that nerves with low glial area or mild damage at
Fig. 3. Eyes show large variability in
their levels of ONH microgliosis at
pre-neurodegenerative ages.
(A) Sequential imaging of the same
ONH area at 3, 4 and 5 months
revealed dynamic changes in GFP+
cell numbers and size; the cross
indicates the ONH center. (B) Total
number of GFP+ cells per ONH at 1, 2,
3, 4 and/or 5 months of age (n=19-59
images per age). Data with eye
identification and late nerve pathology
are presented in supplementary
material Fig. S3. Each bar represents
an individual ONH and green bars
indicate mean±s.e.m. at each age
group (10±1.06, 13.17±1.07, 16.85±
0.77, 16.46±0.94 to 19.93±1.53,
respectively). The average number of
GFP+ cells per ONH rises with age and
significantly increases between 2 and
3 months (**P<0.01; Student’s t-test).
Scale bar: 25 µm.
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10 months showed lowONHmicrogliosis at 3 months. In contrast,
eyes with moderate or severe nerve degeneration, evident by
extensive gliosis or glial scaring, were preceded by intermediate
and high levels of early ONH microgliosis, respectively. The
comparison of the mean ONH microgliosis for eyes grouped by
late nerve pathology revealed significant increases across the three
levels of gliosis (P<0.001 and P<0.05, n=41 eyes; Student’s
t-test). A Spearman’s rank-ordered correlation showed that nerve
glial area at 10 months was significantly correlated with the
number of microglial cells observed at 3 or 4 months (rho=0.56,
P=0.0001; Fig. 5D). These analyses establish a predictive link
between early microglia and/or peripheral monocyte alterations
and later disease progression.
Resident microglia are main components of early ONH and
retinal microgliosis
The selective increase in microgliosis detected prior to optic nerve
degeneration in DBA/2J mice could involve resident microglia and/
or proinflammatory monocyte entry to the ONH, as recently
suggested (Howell et al., 2012). To address whether the early
microgliosis detected by cSLO can be attributed to infiltrating cells,
we assessed ex vivo the expression of sialoadhesin (Siglec-1 or
CD169), which identifies infiltrating monocytes and macrophages,
as well as vitreal hyalocytes and dendritic cells, but is absent in
resident microglia (Butovsky et al., 2012; Davies et al., 2013;
Vagaja et al., 2012). Sialoadhesin-expressing cells are absent in the
brain and retina under physiological conditions, where the blood-
Fig. 4. Late nerve damage is preceded by early microgliosis at the ONH. (A) Experimental design. (B) Live cSLO images of GFP+ cells localized to the ONH
at 3 months of age in Cx3cr1+/GFP DBA/2J mice showing examples of low, medium and high levels of microgliosis. (C) Light-microscopy images of optic
nerve cross-sections at 10 months of age for these same eyes, representative of mild, moderate and severe damage, as assessed by visual scoring.
(D) Microgliosis level, quantified as total number of GFP+ cells per ONH at 1 to 5 months of age (n=19, 31, 60, 36 and 25 eyes per respective age group), plotted for
individual eyes and categorized by their corresponding optic nerve damage score at 10 months of age (color-coded as indicated). (E) Box plots of the same
dataset illustrate significant changes at 3 and 4 months of age (*P<0.05 and ***P<0.001, respectively; Kruskal–Wallis rank ordered test), most notably in the
severe nerves at both ages, and in the moderate nerves at 4 months. Plots indicate the median (thick line), interquartile range (IQR; box height), and data within
1.5 times the IQR (whiskers) or greater (outliers, circles). Scale bars: 250 µm (A) and 50 µm (C).
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brain or blood-retina barrier is intact (Hartnell et al., 2001; Linnartz-
Gerlach et al., 2014; Perry et al., 1992; Sancho-Pelluz et al., 2008).
Immunostaining of retinal whole mounts at 4 months of age
detected only scarce sialoadhesin-expressing cells, and their
numbers were independent of the relative levels of ONH
microgliosis detected by live imaging at 3 months (Fig. 6A,B).
Furthermore, quantification of cells expressing sialoadhesin in the
ONH area at 4 months of age (n=10 retinas; Fig. 6C) detected no
sialoadhesin in 86.60% of CX3CR1-GFP+ cells, colocalization of
GFP and sialoadhesin in 7.39% of cells, and 0.58% of cells
expressing sialoadhesin but not GFP (in only two out of ten retinas).
Consistent with previous reports of monocyte infiltration (Howell
et al., 2012), we detected an increased presence of cells that were
positive for both sialoadhesin and GFP throughout the central retina
in 17-month-old DBA/2J mice (n=4); these cells were localized to
the ONH, the retinal parenchyma and along blood vessels; however,
such cells were infrequent at 4 months of age (Fig. 6D,E). Overall,
these results reveal the presence of a small subset of peripheral
monocytes confined to the ONH area in young DBA/2J mice, and
point to resident microglia as the main cells underlying microgliosis
during early stages of glaucoma progression.
DISCUSSION
Activation of microglia and innate immunity responses have been
linked to the early stages of neurodegeneration (Ajami et al., 2011;
Amor et al., 2014, 2010; Block et al., 2007; Cunningham, 2013;
Davalos et al., 2012; Fuhrmann et al., 2010; Maeda et al., 2011;
Ouchi et al., 2005; Perry and Teeling, 2013; Sapp et al., 2001). In
Fig. 5. Severity of nerve pathology and earlymicrogliosis showa positive correlation. (A) Threshold analysis of the nerve area occupied by glial cells or scar
for the cross-sections in Fig. 4C, and high-magnification views of framed areas. (B) Plot of individual optic nerves from 10-month-old mice sorted by relative glial
area and ascending coverage, and classified as low, medium and high gliosis (15.24±0.96, 30.38±1.67 and 59.05±3.22 mean±s.e.m. non-axonal area,
respectively). Nerves show a spectrum of glaucomatous damage, with significant increases in mean gliosis across groups (***P<0.001; Student’s t-test).
(C) Corresponding microgliosis level or total GFP+ cell number per ONH at 3 months, plotted by their glial area at 10 months (i.e. same order as in B). Microgliosis
is categorized by level as low, medium and high microgliosis (12.63±0.70, 18.43±0.62 and 21.08±0.97 mean cells per ONH, respectively). The mean ONH
microgliosis shows significant increases across levels of nerve gliosis (***P<0.001 and *P<0.05; n=41 eyes; Student’s t-test). Green lines indicate means and
s.e.m. per group. (D) There is significant correlation between the optic nerve glial relative area at 10 months (non-axonal area) and their ONH microgliosis at
3 months (P=0.0001; Spearman’s rank test). Scale bars: 50 µm.
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the retina, microglia activation is also associated with early stages of
disease in animal models of chronic glaucoma (Bosco et al., 2012,
2011; Howell et al., 2011), as well as age-related macular
degeneration (Combadier̀e et al., 2007; Gupta et al., 2003;
Karlstetter and Langmann, 2014; Sennlaub et al., 2013).
However, it has been unclear whether these early responses are
indicative of later severity or patterns of neurodegeneration. Here,
we addressed this using the DBA/2J model of glaucoma, a chronic
model of retinal neurodegeneration that is variable in onset and
progression (Anderson et al., 2001; Chang et al., 1999). Building
upon previous studies of direct in vivo imaging of CX3CR1-GFP+
retinal microglia and infiltrating monocytes using cSLO in models
of acute injury (Alt et al., 2012; Eter et al., 2008; Liu et al., 2012;
Paques et al., 2010, 2006), and morphometric quantification of
microglia activation in live confocal images (Bosco et al., 2015;
Kozlowski and Weimer, 2012), we performed live imaging at early
disease stages, then allowed the animals to age and assessed late
RGC pathology in the optic nerve.
We found that early microgliosis within the ONH is strongly
correlated with later severity of optic nerve degeneration. The
detection of early microgliosis is consistent with previous ex vivo
studies that have reported microglia and/or peripheral monocyte
clustering, activation and proliferation at the ONH prior to
detectable neuronal pathology in this model (Bosco et al., 2011),
Fig. 6. Early microgliosis ismainly driven bymicroglia resident in the ONH. (A) Live cSLO images of two 3-month-old retinas (left) and their ONHs (right, cross
indicating its center), representative of low and high microgliosis. (B) Ex vivo confocal images of the same ONHs at 4 months of age, shown as maximal intensity
projectionof the inner 30 µm.Triple-immunostaining detects fewcells that are positive for bothGFPandsialoadhesinwithin theONH, regardless of their different levels
of microgliosis and activation, revealed by upregulated Iba1 expression in the ONH with increased microgliosis. (C) Number of cells expressing GFP and/or
sialoadhesin per ONH area at 4 months of age. Single- and double-stained cells were quantified in confocal images spanning the central 200 µm of retinal whole
mounts, throughout the inner 60 µm (0.8-µm z-slices). (D) Low magnification, single-slice view of the same 4-month-old retina representative of high microgliosis
(B, bottom row). (E) Comparable view of a 17-month-old retina, showing sialoadhesin expression in perivascular (arrowheads), parenchymal (arrows) and ONH
cells (frame). The ONH area is shown at higher magnification in corresponding insets. Scale bars: 250 µm (A,B,D and E), 25 µm (insets in A, and e).
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as well as early infiltration of proinflammatory monocytes (Howell
et al., 2012). Gene expression studies have also identified the
activation of pathways related to innate immune responses and
monocyte recruitment during early progression of chronic glaucoma
(Fan et al., 2010; Howell et al., 2012; Steele et al., 2006). Previous
studies tracking GFP+ microglia by cSLO after induction of acute
damage to RGCs, by optic nerve crush or intraocular pressure
elevation, have detected increases in retinal microgliosis that were
associated with reduced survival of RGCs (Alt et al., 2012; Liu
et al., 2012). Here, using a chronic model of glaucoma, we found
early microgliosis clustered at the ONH, and were able to link this to
the later severity of optic nerve degeneration. Our findings suggest
that ONH microgliosis might be an early indicator of RGC stress or
damage, consistent with the localization of the earliest axonal
damage to the retina-nerve interface (Howell et al., 2007a; Soto
et al., 2008).
Microglia resident in the unmyelinated optic nerve and
central retina initiate focal microgliosis
Proinflammatory, circulating monocytes infiltrate the DBA/2J ONH
and have been observed in 10.5-month-old animals (Howell et al.,
2012). At young ages, our preliminary analysis suggests that
microglia represent the majority of the CX3CR1-GFP+ cell
population contributing to early microgliosis within the ONH and
central retina, because there are few cells that express sialoadhesin
(Siglec-1 or CD169), a marker of peripheral monocytes and/or
macrophages, as well as of dendritic cells (Asano et al., 2011;
Butovsky et al., 2012; Hartnell et al., 2001; O’Neill et al., 2013),
although it is possible that sialoadhesin expression only identifies a
subset of retinal and ONH peripheral monocytes. Interestingly, we
find in 17-month-old DBA/2J retinas that sialoadhesin is expressed
in the majority of amoeboid monocyte-lineage cells that are
abundant within the ONH and throughout the retina, and which
have been attributed to monocyte infiltration in previous studies
(Howell et al., 2012). Thus, we suggest that early microgliosis is
mainly driven by changes in resident microglia, both in the ONH
and retina. Given the importance of proinflammatory monocyte
infiltration in neurodegeneration (Conductier et al., 2010; Howell
et al., 2012; Naert and Rivest, 2013; Perry and Teeling, 2013;
Ransohoff and Cardona, 2010; Schwartz et al., 2013), it will be
important to explore the crosstalk between microglia and infiltrating
monocytes and/or macrophages during early versus late disease
progression in glaucoma.
The pigmentary form of glaucoma in DBA/2J mice depends upon
mutations in the two melanosomal proteins TYRP1 (tyrosinase-
related protein 1) and GPNMB (glycoprotein nmb) (Anderson et al.,
2001). We have previously shown that early clustering and
activation of microglia was not evident in mice of the congenic
substrain DBA/2J Gpnmb+/SjJ (Howell et al., 2007b). Notably,
GPNMB is also expressed in cells of the macrophage and microglia
lineage, and functions as a repressor of inflammation (Huang et al.,
2012; Libby et al., 2005; Mo et al., 2003; Ripoll et al., 2007; Zhou
et al., 2005). Thus, the early microglial changes documented in the
DBA/2J mouse (Bosco et al., 2015, 2012, 2011; Fan et al., 2010)
could reflect intrinsic immune components, or immune responses to
early stress or damage in RGCs that might contribute to glaucoma
pathogenesis. Nevertheless, ONH and central retinal microglial
alterations represent the earliest retinal change evident in the DBA/
2J mouse, and are strongly correlated with later disease. Although
intraocular pressure is not consistently elevated at young ages in
DBA/2J mice, progressive functional decreases have been detected
after 3 months of age (Saleh et al., 2007). Thus early changes in
RGC function are apparent, consistent with the early changes that
we see in microglia at these ages.
Live, long-term visualization of microglial changes during
neurodegeneration progression and treatment
We conclude that monitoring microglia activation and microgliosis
at prepathological stages might be a powerful tool for detecting the
onset and tracking progression of neurodegenerative disease. The
retina is an ideal region of the CNS to achieve this because specific
cell populations can be directly and repeatedly visualized in the
intact organism by the use of cSLO and cell-selective transgenic
labels (Alt et al., 2012; Chauhan et al., 2012; Eter, 2010; Eter et al.,
2008; Kumar and Zhuo, 2010; Leung et al., 2008a,b; Leung and
Weinreb, 2009; Liu et al., 2012; Nakano et al., 2011; Paques et al.,
2010, 2006; Schallek et al., 2013; Schön et al., 2012; Seeliger et al.,
2005). Previous live imaging studies have used the Cx3cr1GFP/+
transgenic label for cSLO imaging in acute models of induced RGC
injury (Alt et al., 2012; Liu et al., 2012). Here, we applied this to a
chronic progressive neurodegenerative disease, and provided
quantitative analysis of cell changes in the context of chronic
neurodegeneration, by extending the period of tracking for
microglial and/or peripheral monocytic changes over 5 months,
and then analyzing disease progression at 10 months. The tracking
of early microglial changes in young DBA/2J mice offers the
possibility of optimizing the use of this chronic model by allowing
the selection of young animals in which one or both eyes will likely
progress to severe glaucoma at advanced ages, thus reducing the
inter-individual variability in disease progression within
experimental samples. This strategy should advance the already
intense studies aimed at elucidating the complex cellular and
molecular mechanisms that underlie neurodegeneration in chronic
glaucoma (Anderson et al., 2006; Howell et al., 2011; Jakobs, 2014;
Nair et al., 2014; Rieck, 2013; Steele et al., 2006), and identify
initiating events associated with disease onset or early progression
potentially relevant to glaucoma patients.
Other imaging modalities allow quantitative detection of regional
microglia activation in vivo in chronic CNS pathologies, including
positron emission tomography of radioligands for microglia and
astrocyte translocator protein (TSPO) receptors, as well as magnetic
resonance and bioluminescence imaging of neuroinflammation
(Jacobs and Tavitian, 2012; Trapani et al., 2013; Venneti et al.,
2013). However, in vivo visualization of microglia by cSLO
provides cellular resolution, which enables quantitative analysis of
microglia activation based on somal size (Bosco et al., 2015),
similar to analysis of brain microglial activation in two-photon
confocal images (Kozlowski and Weimer, 2012). We observed
highly dynamic and sectorial patterns of microglia activation within
the retinal parenchyma, suggesting that microglia might be
responsive to local changes within the retina during early disease
stages. Given that these changes are complex, this possibility will
be addressed in future studies using early markers of neuronal
stress or dysfunction. Our assessment of microglial behavior near
glaucoma onset demonstrates the power of in vivo retinal imaging to
detect early progression of neurodegeneration at the cell level, with
high spatial and temporal resolution.
We also establish the feasibility of visually tracking induced
changes in retinal microglia activation to assess therapies, in this
case by administering minocycline to decrease activation. With the
development of non-genetic labels for microglia, this could be a
potential tactic applicable to both glaucoma management and
treatment evaluation. Future studies could also evaluate the
possibility of detecting retinal microglia and/or peripheral monocyte
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changes resulting from diverse pathologies because the retina and
optic nerve are targeted for neurodegeneration in diseases such as
Alzheimer’s, Parkinson’s and multiple sclerosis (Chan, 2012;
Frost et al., 2010; Guo et al., 2010; Ikram et al., 2012; Kersten
et al., 2014; Kesler et al., 2011). In line with this, the use of live
detection of retina and ONH pathology for early Alzheimer’s disease
management is under intense study (Ikram et al., 2012; Petzold et al.,
2010; Satue et al., 2014). Overall, our findings suggest that retinal
microglia might serve as sensitive neuroimaging biomarkers to detect
early and/or unidentified stages of disease onset and progression in
glaucoma, and potentially in other neurodegenerative diseases that
impact the retina and optic nerve.
MATERIALS AND METHODS
Mice
Heterozygote Cx3cr1GFP/+ DBA/2J mice were derived by backcrossing
homozygous C57BL/6.129P-Cx3cr1tm1Litt/J mice, which express GFP
under the control of the fractalkine receptor locus, for more than ten
generations (Jung et al., 2000) with DBA/2J mice (Jackson Laboratories,
Bar Harbor, ME). All mice were bred in-house, introducing new breeders
every 3 to 4 generations. This study used females only. Mice were
maintained and imaged in pathogen-free facilities, using protocols approved
by the Institutional Animal Care and Use Committee at the University of
Utah.
cSLO in vivo imaging of GFP+ cells in the retina and ONH
Retinal and ONH GFP+ microglial and/or peripheral monocyte cells were
monitored using confocal scanning laser ophthalmoscope (cSLO) images
collected at monthly intervals in mice aged 1 to 5 months (±1 week),
following a recently reported protocol (Bosco et al., 2015). Eyes with
corneal or iris defects detectable by fundus imaging were excluded from this
study, and imaging was discontinued after 5 months of age, when corneal
and/or iris defects prevented effective pupil dilation and reliable imaging.
Briefly, mice anesthetized by intraperitoneal injection of Avertin (1.3%
2,2,2-tribromoethanol and 0.8% tert-amyl alcohol, Sigma-Aldrich,
St Louis, MO) and fitted with PMMA contact lenses (Cantor & Nissel
Ltd., Northants, UK), were imaged unrestrained with a cSLO system
equipped with a 55° wide-field lens and real-time eye tracker (Spectralis
HRA+OCT, Heidelberg Engineering). The central retina was visualized in
single-point images spanning an area of ∼1.5 mm in diameter, or in
composite images spanning 40 to 60% of the retina (∼1.5×3-4 mm), both
across the inner planes of the retina and ONH (30-40 µm axial depth; 55-60°
focus), using by 820-nm or 488-nm laser excitation (460-490 nm barrier
filter set) to produce fundus and fluorescence images, respectively.
Live image analysis of cell density and morphological activation
To analyze ONH microgliosis, we manually identified and counted total
GFP+ cells within a ∼250-µm-diameter circle centered on the optic disc in
cSLO images. In the surrounding central retina, we performed automated
cell and somal segmentation followed by morphometric analysis using
intensity-based thresholding in cSLO images of the central retina
(∼1.5 mm2) (Bosco et al., 2015). Briefly, individual somal areas were
automatically measured, sorted into groups of activated microglia (>50-
60 µm2), non-activated microglia (10-50 µm2) and manually identified cells
<10 µm2) andmapped to eight radial sectors (∼200 µm2) that subdivided the
central retina and excluded the ONH.
Minocycline treatment
A subset of mice that showed high ONH microgliosis by cSLO imaging at
2 months old (n=9), was administered systemic minocycline (120 mg/kg
body weight, Sigma-Aldrich) on weekdays (Monday-Friday) for 6 weeks,
from 2.5 to 4 months of age, by oral gavage (Bosco et al., 2011).
Mouse tissue collection
Mouse eyes were collected as previously described (Bosco et al., 2011).
Briefly, under full anesthesia induced by inhalation of 2% (vol) Isoflurane in
2 liter/min oxygen, mice were transcardially perfused with 5 ml PBS
followed by 20 ml 4% paraformaldehyde (PFA; Electron Microscopy
Sciences, Hatfield, PA) in 0.1 M PBS circulated with a peristaltic pump
(Dynamax, Rainin, Oakland, CA). Eyes with optic nerves were isolated
from the brain and post-fixed for 2 h in PFA at 4°C, and nerves were
dissected and further fixed overnight in 1.2% PFA and 0.8% glutaraldehyde
in PB (Electron Microscopy Sciences).
Retinal histology
Retinas, with the dorsal pole of the eyes marked with a cauterizer, were
processed as previously described (Bosco et al., 2012, 2008, 2011). Whole-
mount retinas were immunostained using mouse anti human phospho-
neurofilament (pNF, Dako, Carpinteria, CA), rabbit anti-human Iba1
(Wako, Richmond, VA), goat anti-GFP (Abcam, Cambridge, MA), and rat
anti-mouse CD169 (sialoadhesin) conjugated to Alexa Fluor 647 (MOMA-
1 clone, AbD Serotec, Bio-Rad, Raleigh, NC) primary antibodies, which
were detected with Alexa-Fluor-conjugated donkey anti-IgG secondary
antibodies (Invitrogen, La Jolla, CA).
Ex vivo confocal imaging
Confocal images spanning entire retinal flat mounts were generated as
previously described (Bosco et al., 2012, 2011) using a confocal imaging
system equipped with a 20× lens and a resonant scanner (A1R confocal,
Eclipse Ti inverted microscope and NIS-Elements C, Nikon). Multipoint
images (625 xy positions) were acquired at high resolution (0.41 µm/px),
then stitched and projected as maximal intensity of the inner 30-40 µm of
retina (0.8-µm step). To allow image analysis and quantification, the
parameters of image acquisition were maintained constant between retinal
samples, and, for illustration, images had their brightness and contrast
minimally edited. Counts of ONH cells expressing GFP and/or sialoadhesin
where manually performed in the central 200×200 µm around the optic disc,
visualizing each channel independently in maximum-intensity projections,
and verifying colocalization in slice view, through the z plane.
Optic nerve histopathology
Nerves from 10-month-old Cx3cr1GFP/+ DBA/2J mice including the retro-
orbital, myelinated segment (1-1.5 mm post-lamina), were prepared as 1-
µm-thick plastic cross-sections, and stained with a modified
paraphenylenediamine (PPD) protocol and Toluidine Blue (Anderson
et al., 2005; Calkins et al., 2005; Inman et al., 2006; Sappington et al.,
2003). High-resolution multipoint (36 xy) images were generated using a
compound light-microscope and a 60× lens (BX51 and cellSens software,
Olympus, Center Valley, PA).
Quantification of nerve gliosis
By direct visual inspection of high-resolution multipoint images obtained
from entire optic nerve cross-sections, we identified glial cells and the
gliotic scar as areas lacking dystrophic or intact axons, as well as meninges
and vascular lumen. To segment glial areas and vascular spaces, we applied
automatic thresholds to the red RGB channel to generate a binary overlay
representing axon-free nerve areas (FluoRender, University of Utah). To
quantify the relative area occupied by glial cells and/or the gliotic scar, we
measured the cross-sectional area of the nerve and subtracted the area
corresponding to blood vessels and meninges. Random samples
independently segmented and measured by two investigators showed
<5% variation in measured glial area (n=10).
Statistics
Statistical significancewas calculated by a Student’s post-hoc t-test (unpaired,
two tailed; Fig. 2B, Fig. 3B and Fig. 5B,C), by a linear mixed model
(http://CRAN.R-project.org/package=lme4; Fig. 3B) or Kruskal–Wallis rank-
ordered test (Fig. 4E), and is indicated in the graphs as: *P<0.05, **P<0.01
and ***P<0.001. Correlation analysis was performed by Spearman’s rank-
ordered test (Fig. 5D). Analyses were conducted in R: A language and
environment for statistical computing 2014 (R Core Team, R Foundation for
Statistical Computing, Vienna, Austria) or Excel v. 14.4.6 (Microsoft,
Redmond, WA).
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Alterations to myeloid immune cells have been recorded for over a hundred years 
in cases of neurodegeneration, yet the roles these cells play in pathogenesis remains a 
mystery. The rapid and remarkable plasticity of the myeloid system in response to CNS 
injury or disease make answering this question a still formidable task, yet with the newly 
characterized lineages of myeloid cells, it has become increasingly possible.  Since the 
myeloid immune system is so plastic and reactive to stress and injury, genetic and age-
related chronic models are good systems to study it. For this reason, I examined changes 
to myeloid cells in the DBA/2J mouse, a chronic and genetic mouse model of the 
neurodegenerative disease glaucoma. 
Since different parts or compartments of a neuron degenerate at different times, 
models that grant access to these compartments are necessary in order to understand the 
biology of neurodegeneration, and to not overlook potential contributions to pathology 
within different compartments. By comparing degeneration in one compartment with 
another, very surprising discoveries have been made. For example, it has been shown that 
an RGC disconnected from its central targets will persist in the retina for up to 1 month 
(Soto et al., 2008), begging the question of whether these RGCs can be prompted to 
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regenerate. Furthermore, in DBA/2J mice null for the pro-apoptotic gene Bax, it has been 
shown that the axon still degenerates despite preservation of the cell soma within the 
retina (Libby et al., 2005). However, it remains rare for investigators to compare 
degeneration in multiple compartments in a progressive model of neurodegeneration as in 
Schlamp et al. (2006) and even more rare to examine multiple compartments in each 
individual sample. In so doing, my data have revealed selective changes to RGCs within 
the retina that are uncoupled from optic nerve degeneration at that time point. This 
observation raises the question about how functional RGCs might be if only axonal injury 
signaling mechanisms are targeted during the course of disease.  
In addition to the issue of which compartments of a neuron are degenerating, there 
has recently also arisen the question of which lineage of myeloid cell is affecting any 
given aspect of neurodegeneration. Yet there remains a paucity of neurodegenerative 
models wherein the myeloid innate immune system is manipulated and 
compartmentalized neurodegeneration tracked. The DBA/2J mouse is an excellent model 
to examine this issue because changes to both yolk sac derived microglia and 
hematopoietically-derived macrophages occur with disease progression (Bosco et al., 
2011; Bosco et al., 2012; Bosco et al., 2015; Howell et al., 2012). In this dissertation, I 
have described how loss of the neuron to myeloid cell communication system, the 
fractalkine (FKN) system, affected retinal ganglion cell (RGC) compartmentalized 
neurodegeneration and myeloid cell recruitment in the DBA/2J. Additionally, I have 
identified the lineage of myeloid cells both early and later in the DBA/2J thus beginning 
to catalog, in a myeloid lineage-specific manner, changes to these cells throughout 
glaucoma progression in this chronic model.  
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Loss of CX3CR1 signaling differentially worsens RGC 
compartmentalized degeneration 
 
The fractalkine signaling system has been used as a tool to manipulate neuron to 
myeloid cell communication that has resulted in context- or model-dependent 
interpretations as to whether or not this system is neurotoxic or neuroprotective. In 
Chapter 2, I determined in the DBA/2J mouse model of glaucoma that loss of the 
fractalkine receptor (CX3CR1) differentially affected RGC compartmentalized 
degeneration in a manner that was much more subtle than has been reported in more 
acute models of CNS injury/neurodegeneration (Cardona et al., 2006), with selective 
effects on axon transport. This fact highlights the need to analyze multiple neuronal 
compartments using multiple readouts, especially in chronic models of 
neurodegeneration. 
My data suggest that loss of CX3CR1 worsened axonal transport deficits as 
measured by an increase in RGCs that had accumulated axonal proteins, phosphorylated 
neurofilaments (somal pNF+ RGCs) around the cell soma and dendrites, as well as by 
reduced mRNA for the anterograde motor protein Kif1b (25%). The reduction in Kif1b is 
significant because it was also reduced in sectors of DBA/2J retina depleted of RGCs 
labeled with a retrograde axonal tracer (Panagis et al., 2010), suggesting that reduction of 
Kif1b is reflecting loss of axonal transport specifically in RGCs. Further, the reduction 
found in my study likely is an underestimate since it was derived from whole retinas, and 
might have been greater if analyzed in RGCs specifically. The effect of loss of CX3CR1 
was compartmentalized since RGC transcriptional dysregulation and optic nerve 
degeneration were unaffected. Together, these data support the idea of a novel retina-
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specific degeneration pathway where myeloid cells lacking FKN signaling first disrupt 
RGC axonal transport. This finding is important for two reasons. First, it suggests that 
categorizing DBA/2J samples based solely on optic nerve degeneration, which is 
typically done, may miss some potentially early changes to RGCs. Second, the data 
suggest that in order to prevent glaucoma or restore function, the myeloid innate immune 
system of the retina may need to be targeted. Third, it suggests that different mechanisms 
may drive neurodegeneration in different compartments, possibly including loss of 
axonal transport by disrupted neuron to myeloid cell signaling. 
Analyzing all neuronal compartments also allowed me to propose a sequence of 
RGC degeneration, with loss of Brn3 expression happening earlier than accumulation of 
somal pNF or optic nerve degeneration. This result argues that immunostaining for Brn3 
may reveal early stages of glaucoma progression. Indeed, reductions in Brn3+ nuclei in 
DBA/2J have recently been shown at 7 months (Domenici et al., 2014), which is 
significantly earlier than the 10-11 month time point used in this study. In the future, it 
will be interesting to determine at what timepoint the population of Brn3+ somal pNF+ 
cell discovered here initially appears.  
In addition to demonstrating how CX3CR1 affects RGC compartmentalized 
degeneration, my study showed that expression of the phosphatidyl-serine flippase 
Atp8a2 was also reduced. These results are consistent with those of (Zhu et al., 2012) 
who showed that loss of Atp8a2 results in disrupted axonal transport marked by increased 
numbers of RGCs that accumulate somal pNF without showing enhanced optic nerve 
degeneration. I showed by qRT-PCR experiments from whole retina that there was a 
significant reduction (15%) in Atp8a2 mRNA in CX3CR1 null versus control DBA/2J 
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retinas, a reduction that may be understated since whole retinas were used. Another 
limitation of this study was that many of the samples might have been depleted of RGCs 
(as measured by depletion of the RGC specific marker gamma-synuclein) in both the 
control and CX3CR1-deficient retinas thus reducing any potential difference between 
them. Nonetheless, these data implicate loss of Atp8a2 in the process of 
neurodegeneration. To further examine the role of Atp8a2 in this disease model, I would 
monitor its expression at earlier time points, especially since loss of axonal transport 
occurs relatively earlier in the DBA/2J (Crish et al., 2010). Since gene expression 
profiling data from cortex indicates that Atp8a2 can be expressed by neurons or microglia 
(Zhang et al., 2014), it will also be important to determine which cells in the retina 
express Atp8a2.  If Atp8a2 is expressed in microglia, then it supports the hypothesis that 
loss of function in microglia causes a specific RGC pathology (loss of axonal transport). 
This would be an impactful finding because there is currently a lack of direct evidence 
that a loss of function in microglia contributes to neurodegeneration. Conversely, if 
Atp8a2 is expressed in RGCs, then it would implicate phosphatidyl-serine and the 
receptors that bind it as a molecular mechanism for early axonal transport deficits that are 
seen in many models of neurodegeneration such as Alzheimer’s disease, multiple 








Future experiments examining how loss of CX3CR1 affects RGC 
compartmentalized degeneration 
While my data demonstrated compartmental changes that are consistent with 
reductions in axonal transport, I did not measure this directly. To more directly assess 
RGC axonal transport, we will use intravitreal injection of Cholera-toxin B (CTB) 
conjugated to fluorophores, since CTB requires uptake and active transport from RGCs to 
the superior colliculus. Since Crish et al. (2010) showed that axonal transport deficits can 
happen very early in the DBA/2J, we will analyze CTB levels in the superior colliculus at 
the 8-month time point, when they first noticed a majority of animals had anterograde 
axonal transport deficits, to determine if loss of CX3CR1 affects this readout. Another 
limitation of my study was the use of whole retina in qRT-PCR experiments that might 
have masked a greater reduction in gene expression in candidate genes such as Kif1b in 
RGCs. Since anterograde transport is disrupted early in the DBA/2J (Crish et al., 2010), 
and Kif1b carries important neuronal cargos such as mitochondria and synaptic vesicles 
(Zhao et al., 2001), getting a more precise answer as to the levels of Kif1b down-
regulation in RGCs from CX3CR1 null DBA/2J retinas would be insightful. This could 
be accomplished by purifying RGCs through immunopanning and RNA extraction 
(Ivanov et al., 2006). Additionally, while my data show no effects on optic nerve 
degeneration at this stage, I assessed this only in the proximal optic nerve. I selected this 
region because it is thought to be the initial site of damage to RGC axons. However, as 
Crish et al. (2010) demonstrate, there are a greater number of dystrophic axonal profiles 
more distally in the DBA/2J optic nerve. Thus, it is possible that loss of CX3CR1 
affected degeneration more distally first and that the proximal location simply had not 
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been affected at the 10-month timepoint. Therefore, now that we have developed better 
tools to assess optic nerve degeneration, it will be interesting to examine the degeneration 
of the optic nerve and optic tract past the chiasm at several more distal points at 10 
months. At the same time, since we do not understand the relationship between myeloid 
cells and axon degeneration, we will sample for dystrophic profiles and examine myeloid 
activation in these areas. These future experiments will give a more complete answer to 
the question: did loss of CX3CR1 uncouple retinal from optic nerve degeneration, or did 
it just do so in the proximal optic nerve?  
All together, these data demonstrate that loss of CX3CR1 affects 
neurodegeneration in a compartmentalized rather than general manner, and links the 
myeloid system to axonal transport deficits frequently seen in neurodegeneration. My 
findings also urge caution when extrapolating results from acute models to chronic ones, 
since loss of CX3CR1 in acute contexts has much more dramatic effects (Cardona et al., 
2006). My findings also suggest that earlier pathways that potentially affect RGC 
function might be found by profiling RGCs according to pathology in the retina rather 
than the optic nerve.  
 
Loss of CX3CR1 signaling increases macrophage infiltration 
but not myeloid activation overall 
 
One of the major issues with determining the role of the myeloid innate immune 
system in neurodegeneration is that few investigators have manipulated it and examined 
how compartmentalized neurodegeneration was affected. In order to address this issue, I 
analyzed myeloid cells in the DBA/2J retina and determined that rather than increasing 
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microglial activation across all myeloid cells, loss of FKN signaling increased 
macrophage infiltration. I showed that amoeboid Iba1+ cells were CCR2+ and localized 
to the surface of the retina, as is the case for macrophages infiltrating in response to 
injury (Garcia-Valenzuela and Sharma, 1999) or screening the vitreous (Vagaja et al., 
2012). However, despite this increase in amoeboid Iba1+ cells, the numbers of these 
macrophages did not correlate with RGC pathology. Lastly, numbers of presumed 
resident microglia were unchanged, total levels of Iba1 mRNA were unaffected, and there 
was no difference in microglia morphology after loss of CX3CR1, suggesting that 
microglia activation was not increased. However, I cannot rule out specific molecular 
changes to microglia that affect their function. All together, these data demonstrate that 
loss of CX3CR1 increases macrophage infiltration rather than overall myeloid activation, 
consistent with the findings of Sennlaub et al. (2013) in a mouse model of age-related 
macular degeneration. However, in contrast to the finding of Sennlaub et al. (2013), who 
showed that infiltrating macrophages on a CX3CR1 background increased neuronal 
apoptosis, I found that the numbers and distribution of infiltrating macrophages were not 
correlated to the RGC pathology that I measured. To determine whether microglia or 
infiltrating macrophages are contributing to RGC pathology, it will be important to 
determine the effect of loss of CX3CR1 in a myeloid lineage specific manner. My data 
are consistent with the hypothesis that a loss of function in resident microglia led to a 
reduction in RGC axonal transport, but so far the role of either resident microglia or 





Figure 4.1: Proposed model for how loss of CX3CR1 affects retinal ganglion cell 
axonal transport, resident microglia, and CCR2+ infiltrating macrophages in the 
DBA/2J. (A) Overall the data are consistent with a loss of function model amongst 
resident microglia (branched green cell) that reduced axonal transport in retinal ganglion 
cells. Macrophage (green clouds) infiltration is increased but it is unclear what relation 














Future experiments examining how loss of CX3CR1 affects myeloid  
function and lineage specific roles in RGC neurodegeneration 
 
While my data did show an increase in infiltrating macrophages, I did not stain 
branched microglia with a verified resident microglial marker such as CD39 or P2Y12. It 
remains possible, then, that peripheral macrophages infiltrated, downregulated CCR2, 
and adopted a branched shape as resident microglia, although the literature in other 
neurodegenerative diseases suggests this does not happen (Ajami et al., 2011). Some 
antibodies to these resident microglia markers exist, but another approach would be to 
intravenously inject EdU to label the more quickly proliferating monocytes as in 
Sennlaub et al. (2013). Other authors have noted upregulation of pro-inflammatory 
cytokines with loss of CX3CR1, which I did not address in my study. In particular, Il-1β 
and Tnf-α have been shown in multiple studies to be upregulated (Cardona et al., 2006; 
Mizutani et al., 2012; Zujovic et al., 2000). It would be important to quantify these in 
CX3CR1 null DBA/2J retinas, because upregulation of these cytokines would be 
consistent with a neurotoxic gain of function in myeloid cells.  
An interesting question raised by my study is what are the direct roles of   
macrophages or resident microglia in RGC compartmentalized pathology? Manipulating 
these cells in a myeloid lineage-specific manner is the only way to untangle their 
contributions to pathology and answer whether a loss, a gain of function, or some 
combination contributed to neurodegeneration. Further, since the contributions of 
myeloid cells can vary wildly from being pro-regenerative to degenerative, it is crucial to 
more carefully tease apart their contributions (Block et al., 2007; Cui et al., 2009). 
Until there is a more mechanistic understanding of these different myeloid 
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lineages, ablation experiments can be utilized to test their contributions to pathology. 
For example, macrophages can be ablated as in El Khoury et al. (2007), who showed that 
macrophages did not accumulate in a mouse model of Alzheimer’s disease on a CCR2 
genetically ablated background. In order to directly test the role of macrophages in 
glaucoma, existing CCR2 knock out mice could be backcrossed onto the DBA/2J 
background and tested for the RGC pathology measured here. Alternatives to this genetic 
approach include injecting clodronate liposomes to eliminate infiltrating macrophages at 
times selected based on the appearance of CCR2+ macrophages in the DBA/2J, although 
repeated injections may be necessary due to the variable age of onset and prolonged 
course of disease.   
In contrast to infiltrating macrophages, it remains challenging to ablate resident 
microglia.  Since microglia are dependent on CSF1R signaling for survival, 
administration of a CSF1R antagonist (Elmore et al., 2014) can be used to ablate 
microglia with apparently minimal effect on macrophage numbers (Mok et al., 2014). As 
Elmore et al. (2014) demonstrated, there might be a microglial stem cell that repopulates 
the CNS with microglia after ablation, such that chronic dosing of this drug may be 
necessary. However, since RGCs also express the CSF1R, there is concern that the drug 
may have direct effects on the RGCs (Lindqvist et al., 2010). An alternative option for 
microglia ablation would be to use existing mice with a floxed CSF1R allele crossed with 
mice expressing a tamoxifen inducible Cre driven by the CX3CR1 promoter (Goldmann 
et al., 2013). In these mice, specific ablation of microglia may be achieved in adult mice 
after administration of tamoxifen, without injury to the eye. It would be necessary in 
these mice to monitor levels of macrophages to measure the potential confound of 
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toxicity to these cells. If this strategy proves too toxic, AAVs that express Cre driven 
from an F4/80 promoter that target microglia (Cucchiarini et al., 2003) can be injected 
intravitreally in mice expressing the floxed CSF1R.  
Ultimately all myeloid ablation experiments suffer from a potential interference 
with myeloid cell homeostatic functions. In addition, if injury is required for the ablation, 
there may be confounding effects from toxic gain of functions.  Thus, it would be more 
ideal to selectively excise the CX3CR1 gene in circulating monocytes or resident 
microglia and measure how this affects RGC pathology such as axonal transport. These 
experiments are also more consistent with potential therapies than cell lineage ablation 
paradigms. To date, the existing tools disrupt the CX3CR1 gene throughout the entire 
animal whether by GFP or Cre insertion at the CX3CR1 locus (Goldmann et al., 2013). In 
the absence of more specific tools, carefully controlled bone marrow chimerism 
experiments alongside measures of RGC pathology may address whether resident 
microglia or macrophages drive RGC degeneration. With shielding the head, the roles of 
these two myeloid lineages cells can be assessed by grafting wild type marrow into 
CX3CR1 null DBA/2J and CX3CR1 null marrow into wild type DBA/2J mice, 
respectively, and measuring RGC pathology. If resident microglia are responsible for an 
increase in somal pNF+ RGCs as Chapter 2 suggests, then there will be more somal 
pNF+ RGCs in the CX3CR1 null animal reconstituted with wild type marrow than the 
converse.  
The most useful experiment would be to conditionally and genetically inactivate 
CX3CR1 using a floxed allele that would only be excised by resident microglia or 
macrophages.  Currently, we lack the specific Cre drivers to accomplish this inactivation, 
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but there is an increasing list of resident microglia and peripheral macrophage specific 
markers that may soon allow this experiment to be accomplished (Butovsky et al., 2014; 
Butovsky et al., 2012; Hickman et al., 2013; Saederup et al., 2010; Zhang et al., 2014). 
With these tools, the direct role of FKN function in either resident microglia or 
macrophages can be assessed in terms of their effect on RGC pathology. 
All together, my findings implicate myeloid cells in neurodegeneration, and 
demonstrates to the field that loss of CX3CR1 in a chronic neurodegenerative context 
increases macrophage infiltration but not myeloid cell activation overall. The lack of 
correlation between infiltrating macrophages and RGC pathology is inconsistent with the 
model of a neurotoxic macrophage, and hints that resident microglia may have been 
responsible for the apparent disrupted axonal transport in the DBA/2J glaucoma model, 
and possibly in other neurodegenerative diseases.  Interestingly, this lack of correlation, 
in combination with the apparent lack of change to resident microglia, raises the question 
of whether a loss of homeostatic myeloid function can contribute to neurodegeneration. A 
possible candidate gene for this mentioned above is Atp8a2. If a loss of function is found, 
it would be the first direct link between microglial function and neuronal pathology that 
has long been suggested but not shown by the literature. Additionally, any toxic gain of 
functions found in resident microglia would help to develop new therapies.    
 
Early microgliosis correlates with later optic nerve degeneration 
 and is composed of resident microglia 
 
Although microglial activation had been demonstrated to occur in a subset of 
DBA/2J mice at 3 months in the retina (Bosco et al., 2011), it was unclear whether there 
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was any relationship to glaucoma progression. Additionally, given the findings that 
macrophages do infiltrate the DBA/2J retina (Howell et al., 2012), whether these 
CX3CR1+ cells were resident microglia or macrophages was a relevant question. This 
study (Bosco et al., 2015), described in Chapter 3, used confocal scanning laser 
ophthalmoscopy (cSLO) in vivo imaging at 3 months, assessment of optic nerve 
pathology at 10 months, and immunostaining using myeloid lineage-specific markers to 
answer these questions. We determined that early microgliosis is a strong predictor of 
later optic nerve pathology. We also determined that this early microgliosis was 
composed of resident microglia.  
I contributed in crucial ways to both of these questions. Pathology in the optic 
nerves was scored by a novel analysis technique using binary masks to determine the 
percentage of optic nerve composed of non-axonal elements being glia and extracellular 
matrix. I created these masks and quantified the % non-axonal elements from these masks 
in order to establish the key correlation between early microgliosis and later optic nerve 
pathology. I also determined that there were very few peripheral macrophages 
(CD169/Sialoadhesin+ cells) in 3-month-old DBA/2J mice and validated the use of 
CD169 in LPS intravitreally injected mice, as well as in older DBA/2J animals. This 
demonstrated that microgliosis at 3 months was composed of resident microglia, 
confirmed earlier reports of macrophage infiltration in the DBA/2J (Howell et al., 2012), 
and was the first study to show CD169+ cells entering the retina in a model of glaucoma. 
One caveat to this study is that resident microglial markers were not used to positively 
identify the resident microglia. Recently, some options such as antibodies to P2Y12 and 
CD39 have been generated and could be validated in an LPS intravitreal injection 
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paradigm with markers of peripheral macrophages such as CCR2 and the resulting whole 
mounts analyzed for co-localization. The data predict there will not be co-localization, 
but the expression of these resident microglial markers remains unknown in the context 
of injury or within the retina. Alternatively, an existing CX3CR1 promoter-driven 
estrogen receptor-inducible Cre mouse exists that when crossed to a rosa26-driven lox-
stop lox YFP mouse can label resident microglia. This double transgenic mouse takes 
advantage of the fact microglia are a stable population while monocytes proliferate and 
turn over. This mouse has already been used to stably label microglia with YFP at 5 to 7 
weeks, while after 1 week of tamoxifen exposure less than 0.2% of circulating Ly6clo 
monocytes were labeled (Goldmann et al., 2013). These two constructs could be bred 
onto the DBA/2J background or used in Bl6 mice to verify resident microglia-specific 
markers.   
One model in the field suggests that neuronal damage activates microglia which 
then become chronically activated, setting up a vicious cycle further damaging neurons 
(Block et al., 2007). The finding that microglial activation at 3 months in the DBA/2J 
retina correlates with later optic nerve degeneration, in combination with the beneficial 
effect of head-only irradiation at 3 months to ablate proliferating microglia, supports this 
model (Bosco et al., 2012; Howell et al., 2012). However, this model remains to be 
directly tested and has not been examined in a compartmental manner. Perhaps early 
microgliosis is beneficial for RGC compartments within the retina but not the nerve.  It 
also will be important to determine the time course of RGC pathology in mice that have 




Future experiments generating a time course of RGC  
degeneration in the DBA/2J 
 
The existing tools that I have used and helped verify in Chapter 2 could be used to 
answer these questions. cSLO imaging could be used to identify retinas with intense 
microglial activation and these could be stained with the RGC transcription factor Brn3 
and phosphorylated neurofilament alongside histologic analysis of optic nerve 
degeneration as was done in Bosco et al. (2015). In particular, since Brn3 can be reduced 
as early as 7 months in some DBA/2J retinas (Domenici et al., 2014), it would be 
interesting to answer the question of how this loss of RGC transcription factors relates to 
microglial activation at 3 months. To date, establishing a true time course of pathology in 
the DBA/2J has been technically challenging because of the variability of the phenotype, 
resulting in large numbers of mice needed for analysis, and the assumption that pathology 
was not apparent until 10 months in most animals (Schlamp et al., 2006). However, with 
our new technique of imaging the eye to detect microgliosis at young ages, a sample 
could be enriched for sick retinas, potentially allowing better analysis of the time course. 
Further by comparing mice with different timings of microglial activation, it could be 
determined if there is a stereotyped sequence of pathology or whether different mice 
progress differently in the retina or optic nerve. These investigations might implicate new 
genes in glaucoma and neurodegeneration.  
In addition to RGC pathology, using cSLO live imaging would allow us to ask 
how microglia in an activated retina are different from a quiescent retina. Since we know 
that the microglial activation at 3 months is composed of resident microglia that in 
Cx3CR1gfp/+ animals express GFP, it would be simple to use flow cytometry to isolate 
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them and then profile them by RNAseq or qRT-PCR for candidate genes.  
In addition to profiling microglia, with the cSLO imaging tool we could 
determine whether early microglia activation correlates with other early RGC pathology 
readouts that have been noted in the DBA/2J. For example, Crish et al. (2010) noted 
disrupted anterograde axonal transport in some DBA/2J mice at 3 months, and Saleh et 
al. (2007) found a reduction in pattern electro-retinogram amplitude (PERG, a measure of 
RGC electrical activity) at this same time point. Animals with intense microgliosis at 3 
months could then be identified by cSLO, PERG amplitude measured, and anterograde 
axonal transport determined directly by fluorophore conjugated CTB intravitreal 
injection. If early microgliosis correlates with either of these readouts, it could then more 
directly be manipulated through ablation experiments or pharmacologically with 




My work provides the framework necessary to evaluate the contributions of the 
myeloid innate immune system to chronic neurodegeneration. Models such the DBA/2J 
are critical to the neurodegenerative field, despite the technical limitations such as sample 
size and time constraints, because they provide a genetic, spontaneously arising 
neurodegenerative phenotype. However, if these models are not assessed in a 
compartmentalized manner, selective impacts to neurodegeneration may be missed. The 
case of loss of CX3CR1 exemplifies these principles. If my analysis of CX3CR1 null 
DBA/2J mice had solely focused on the integrity of the optic nerve, then the conclusion 
would have been that fractalkine signaling has no role in glaucoma progression. In 
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contrast, I found a retina-specific contribution of myeloid cells to RGC degeneration. 
Additionally, my work on microglial changes at 3 months in the DBA/2J has laid the 
groundwork for a study of compartmentalized time course of RGC pathology that could 
put forth a strong sequence of degeneration.   
My work also begins to lay the foundation for determining how myeloid lineage 
specific cells contribute to neurodegeneration. These cells are crucial because they not 
only drive neurodegeneration, but also may be harnessed to ameliorate it as peripheral 
macrophages have been shown to do for amyloid-β deposition. However, it has been 
challenging to study them, since they are so rapidly plastic, derive from different myeloid 
lineages, and may therefore play different roles in neurodegeneration. My work 
demonstrates that the DBA/2J retina is a good model to study these cells because both 
resident myeloid cells and macrophages are involved. Further, I have shown that these 
infiltrating macrophages can be labeled without the need for genetic markers. Already the 
tools I have helped develop have suggested that these macrophages may be playing a 
different role, rather than driving pathology. With these markers and knowledge of which 
pathology to score, more direct tests of the role(s) that resident microglia and macrophage 
play in neurodegeneration can be performed. Studies targeting one myeloid population or 
the other may discover unknown genes that operate within the immune system to alter 
neurodegenerative progression. Furthermore, investigators can begin to ask how does one 
arm of the myeloid system alter the other? The contribution of resident microglia to 
neuronal pathogenesis, whether for good or ill, has also long intrigued investigators. If 
resident microglia do contribute to axonal transport deficits in a loss of function manner, 
this might suggest a positive homeostatic role played by microglia. Ultimately, my work 
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should help answer the question of whether a gain or loss of function within resident 
microglia or macrophages contributes to neurodegeneration, information that will be 
important not only for glaucoma but for many other neurodegenerative diseases. Further, 
studying microglia in age-related diseases may reveal how the function of these constant 
gardeners change over time and shed light on the reasons why some individuals become 
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